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bp 
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LCR 
— 
long control region 
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NLS — nuclear localization signal 
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RE 
— responsive enhancer 
SDS-PAAG 
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TAD — transactivation domain 
URR — upstream regulatory region 
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— 
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1. INTRODUCTION 
The papillomaviruses are small DNA viruses that induce squamous epithelial 
proliferative lesions (warts) in their natural hosts. Papillomaviruses maintain 
latency in dividing stem cells of various epithelial tissues, replicating as extra-
chromosomal plasmids. The virus life cycle is greatly regulated by the viral 
transcription factor E2. First, the bovine papillomavirus E2 protein regulates 
viral protein levels by modulating the transcription of viral genes. Second, E2 is 
responsible for initiation of DNA replication; it activates viral replication 
through co-operative binding with the viral initiator protein El to the origin of 
replication. The third function of E2 is to aid in the faithful segregation of viral 
DNA, the E2 protein is responsible for chromatin association of the viral 
genome during the mitosis. 
The bovine papillomavirus (BPV1) E2 is a DNA binding protein. Proteins 
that recognize specific DNA sequences generally determine when and to what 
extent activities such as DNA transcription and replication occur. In the present 
thesis, I would like to give an overview how the functional activities of the E2 
protein are regulated through the structure of the protein, and through its 
activity to bind to DNA in a sequence-specific manner. 
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2. REVIEW OF LITERATURE 
2.1. The genome structure and organization of BPV1 
Papillomaviruses (PV) are small DNA viruses that infect a wide variety of 
vertebrate species and induce squamous epithelial proliferative lesions (warts) 
in their hosts. Papillomaviruses are highly species-specific. They infect both 
cutaneous and mucosal epithelial tissues at different body sites: skin, mouth, 
throat, anogenital tract and others. Viral gene expression, replication, episomal 
maintenance and virus assembly are tightly linked to the differentiation status of 
epithelial cell. Complete viral particles are shed from the terminally differen­
tiated cells of the outer dermis, while the undifferentiated stem cells are pre­
sumed to maintain the viral genome. Papillomaviruses are nonenveloped, 
icosahedral particles approximately 54 nm in diameter. Their virions contain 
covalently closed, circular double-stranded DNA genomes of approximately 
8 kilobases. The length of the BPV1 genome is 7946 bp (Ahola et al, 1983; 
Chen et al., 1982). All papillomaviruses share a similar genome organization, 
their translational open reading frames (ORF-s) locate on one strand of viral 
DNA (Engel et al, 1983). The genomes of several papillomaviruses have been 
sequenced and found to contain three distinct regions: (1) an upstream regu­
latory region that controls transcription and replication; (2) early genes en­
coding proteins required for transcription, DNA replication, and cell trans­
formation; and (3) two late genes encoding the major and minor capsid protein. 
The upstream regulatory region (URR; also called "long control region" 
(LCR)) is located between the 3' end of the late region and 5' part of the early 
region and is approximately 1 kb long. The URR contains eis elements neces­
sary for the regulation of transcription and replication. There are also two poly-
adenylatiori sites in the genome, one common for the early genes (locating 
between the early and late region) and the other specific for the late gene 
expression (in URR). 
The early region of the genome comprises open reading frames for El, E2, 
E3, E4, E5, E6, E7 and E8 proteins. The El protein is a viral replication factor, 
which has ATPase, DNA-helicase and DNA-unwinding activities (Section 
2.3.2). The E2 protein is viral transactivator, which binds to its cognate binding 
sites throughout the viral genome activating viral promoters and replication 
origin (Section 2.4). The E5, E6 and E7 ORF-s encode for the transforming pro­
teins of papillomaviruses. The BPV1 E5 has been found to be the major onco­
gene in BPV, being both necessary (DiMaio et al, 1986; Schiller et al., 1986; 
Yang et al., 1985) and sufficient (Bergman et al, 1988; Leptak et al., 1991) for 
transformation. E5 protein induces cellular proliferation and abrogation of con­
tact inhibition, resulting in oncogenic transformation. It is highly hyrdophobic 
protein anchored into the cell membrane and can interact with other membrane-
associated proteins, the receptors for PDGF (the platelet derived growth factor) 
and EGF (the epidermal growth factor), resulting in receptor activation. These 
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interactions are probably sufficient to mediate cell transformation (Martin et al., 
1989; Nilson and DiMaio, 1993). BPV E6 and E7 facilitate anchorage-
independent transformation and are both required for full transformation of 
mouse C127 cells (Neary and DiMaio, 1989). The BPV1 E6 oncoprotein has 
been shown to transform CI27 cells and to stimulate transcription when 
targeted to a promoter (Lamberti et al., 1990). Recently it was shown that BPV1 
E6 mediates sensitization of cells to TNF (Tumor Necrosis Factor) induced 
apoptosis (Rapp et al., 1999). ORF E4 protein is associated, with late gene 
expression (Neary et al., 1987). The late ORF-s code for the structural proteins 
of the virus capsid, LI and L2, which are transcribed in the upper layers of 
infected epithelia or epidermis and are expressed only in late phase of the viral 
replication (Engel et al., 1983). 
2.2. Regulation of BPV1 gene expression 
BPV1 is transcriptionally active in both keratinocytes and fibroblasts in vivo 
(Baker and Howley, 1987). As illustrated in Fig. 1, there are at least six BPV1 
promoters that are active in fibroblasts and lower level keratinocytes in vivo as 
well as in BPV1 transformed fibroblasts in culture; these are therefore con­
sidered to correspond to early gene promoters. Several early BPV1 mRNAs 
start at a major promoter upstream of the E6 gene, P89. In addition, there is at 
least one major promoter that is utilized only in the upper epidermal layer; this 
is thought to be the viral late gene promoter, designated PL (Baker and Howley, 
1987). The URR contains a constitutive enhancer (CE) (Vande Pol and Howley, 
1990; Vande Pol and Howley, 1992), which is not dependent on the virally 
encoded proteins and two others (E2RE1 and E2RE2) that are E2 responsive 
(Spalholz et al., 1987). 
The E2 ORF encodes a family of proteins which form the central regulatory 
system of the virus, controlling directly both viral gene expression and 
replication. E2 acts as a transcriptional activator by interacting with E2 binding 
sites, thereby enhancing transcription of all early viral transcripts (Szymanski 
and Stenlund, 1991). The E2 proteins are expressed from several different viral 
promoters. The E2 ORF encodes a transactivator (E2TA) which is expressed 
from the P89, P89o and P2443 promoters (Hermonat et al., 1988 Spalholz et al., 
1987; Spalholz et al., 1985). The E2 ORF also encodes two transcriptional 
repressors. Repressor protein E2C is expressed from the P3080 promoter and 
translated from an internal methionine at amino acid 162 of the E2 ORF. 
Another repressor E8/E2 is expressed from P89o and encoded by a spliced 
message that encodes 11 amino acids from the E8 ORF linked to the C-terminal 
207 amino acids of E2 via the splice acceptor at nucleotide 3225 (Choe et al., 
1989; Lambert et al., 1989b; Lambert et al., 1987). The E2TA as well as 
repressors E2C ans E8/E2 bind to DNA and share capacity to dimerize with 
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Figure 1. Map of the BPV1 genome. 
Solid boxes represent the 17 E2 binding sites found in the genome. The open bars let­
tered El to E8, and LI and L2 represent the ORFs. The upstream regulatory region 
(URR), which bears the E2-responsive elements (E2RE), is enlarged at the bottom. 
themselves and with each other (McBride et al., 1989; Monini et al., 1993; 
Prakash et al., 1992). The promoters from which the E2 gene products are 
expressed are themselves E2-responsive and therefore could be autoregulated 
by the E2 proteins (Hermonat et al., 1988; Vaillancourt et al., 1990, Haugen et 
al., 1987; Szymanski and Stenlund, 1991). All three E2 polypeptides have been 
identified in BPV1 transformed cells (Hubbert et al., 1988; Yang et al., 1991b). 
The relative abundance of repressor over transactivator proteins in transformed 
C127 cells (1 E2TA: 10 E2C: 3 E8/E2) is thought to be important for the regu­
lation of the activity of full-length E2 protein (Hubbert et al., 1988). The ratio 
of the three E2 proteins changes throughout the cell cycle with the ratio of E2 
transactivator to repressors being highest at S phase and lowest at Gl (Yang et 
al., 1991b). By controlling the balance of viral activator and repressors, regu­
lation of plasmid copy number is achieved. Both the competitive DNA binding 
at the E2 DNA binding sites and formation of heterodimers between E2TA and 
repressor molecules are proposed as potential mechanisms by which the repres­
sor molecules inhibit E2TA. Repressors of the E2 protein have been shown to 
regulate viral transformation (Choe et al., 1989; Lambert et al., 1987; Riese et 
al., 1990), transcription (Barsoum et al., 1992), transient DNA replication (Lim 
et al., 1998) and plasmid copy number (Lambert et al., 1990; Riese et al., 
1990). 
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2.3. Papillomavirus DNA replication 
Papillomaviruses infect basal epithelial and mucosal cells in a wide range of 
different hosts. Papillomavirus genome replication can be generally described 
as a three-step process (Howley, 1996). After the initial entry into the basal 
cells, the viral genomes are quickly amplified in the host cell nucleus. At the 
next, maintenance stage, the viral DNA replicates at a constant copy number per 
cell in the proliferating host cells. Papillomaviruses are able to maintain their 
genome extrachromosomally for prolonged periods with significant stability. 
The final, vegetative amplification stage, where the formation of new infectious 
particles occurs, takes place only after the host cells have terminally diffe­
rentiated into keratinocytes. 
The replication of BPV 1 in vivo requires two viral proteins, El and E2, both 
of which bind to DNA site specifically, and a short DNA sequence called 
"origin of replication" (Ustav and Stenlund, 1991; Ustav et al., 1991). However, 
the minimal origin of replication, consisting of El and E2 binding sites alone, is 
not sufficient for stable maintenance of BPV1 episomes. Additional region from 
URR containing at least six E2 binding sites are required for stable maintenance 
(Piirsoo et al., 1996). Papillomavirus DNA replication is not cell type specific, 
despite a high degree of host and cell-type specificity for infection. BPV 1 can 
replicate in a number of mammalian cells of epithelial and fibroblast lineage if 
El and E2 proteins are provided from heterologous expression vector (Chiang 
et al., 1992). BPV1 DNA replication in vitro has been reconstituted with 
purified proteins and cell extracts from murine, simian and human cells (Bonne-
Andrea et al., 1995a; Melendy et al., 1995; Muller et al., 1994; Yang et al., 
1991a). The cellular factors essential for papillomavirus DNA replication are 
provided by the host cell and include replication protein A (RPA), replication 
factor C (RFC), proliferating-cell nuclear antigen (PCNA), and topoisomerase I 
and II as well as DNA polymerase a-primase complex and DNA polymerase 8 
(Melendy et al., 1995; Muller et al., 1994). In addition, the cellular factor CDE1 
binding site in early coding region stimulates the replication of BPV 1 in vivo 
(Pierrefite and Cuzin, 1995). The results from in vitro studies are generally in 
agreement with the in vivo results; however, a very modest effect of added E2 
protein and dependence on the presence of an E2BS at the ori are observed in 
vitro. At a higher concentration the El protein alone is able to support in vitro 
BPV1 DNA replication (Bonne-Andrea et al., 1995a; Bonne-Andrea et al., 
1997; Muller et al., 1994; Yang et al., 1991a; Yang et al., 1993). 
2.3.1. The origin of replication 
The BPV1 origin of replication consists of E2-binding site (E2BS), an A+T-rich 
sequence and the palindromic sequence that constitutes the El-binding site 
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(E1BS) (Ustav et al., 1993; Ustav et al., 1991). A functional replication origin 
has been reconstituted using oligonucleotide cassettes corresponding to three 
sequence subelements of BPV replication ori (McSahn and Wilson, 1997). This 
work revealed that a functional origin required at least one copy of all three 
subelements. 
The transcription factor E2 binds to the consensus sequence 
ACCG(N4)CGGT (Androphy et al., 1987; Hawley-Nelson et al., 1988; Li et al., 
1989). Results from the studies of the BPV ori indicate that the requirement for 
an E2BS is absolute, but a great deal of flexibility exists in terms of both the 
position and and the affinity of the E2BS. A single E2BS of very low affinity is 
sufficient for an active ori, at least under conditions where El and E2 are over-
expressed (Ustav et al., 1993; Ustav et al., 1991). A relationship appears to 
exist between the affinity of the E2BS and the ability to function at a distance 
from the binding site for El (Ustav et al., 1993) (Sedman and Stenlund, 1995). 
In multimerized form, the E2BSs are able to function even when placed at a 
distance of several kilobases from the rest of the ori. Gillette and Borowiec 
have demonstrated that the presence of both E2-binding sites (E2BS11 and 
E2BS12) within the origin is necessary for wild-type replication activity in vivo-, 
BS11 and BS 12 play separate but synergistic roles in the initiation of viral DNA 
replication that are dependent on their location within the origin (Gillette and 
Borowiec, 1998). 
The binding site for the El replication helicase has been defined in BPV as 
an imperfect palindromic sequence ATTGTTGTTAACAATAAT (Holt et al., 
1994; Ustav et al., 1991; Wilson and Ludes-Meyers, 1991; Yang et al., 1991a). 
It has been shown that single point mutations in the BPV El BS can reduce 
binding of El, as well as replication, more than 20-fold (Sedman and Stenlund, 
1995). 
The A+T-rich sequence of the minimal BPV ori is important for replication 
in vivo, since a deletion of this sequence results in a drop in replication activity 
(Ustav et al., 1991). While the E1BS and E2BS are sequence-specific elements, 
the BPV1 A+T-rich sequence can be at least partially substitute with hetero­
logous A+T-rich sequences, suggesting that the role of this element is primarily 
AT content-dependent rather than sequence-dependent (McSahn and Wilson, 
1997). 
2.3.2. Assembly of the replication initiation complex at ori 
The viral El protein is absolutely required for papillomavirus DNA replication, 
both in vivo and in vitro (Bonne-Andrea et al., 1995a; Ustav and Stenlund, 
1991; Yang et al., 1991a). The El protein is a 72 kD nuclear phosphoprotein 
with a sequence-specific DNA binding activity (Blitz and Laimins, 1991; Chen 
and Stenlund, 1998; Lentz et al., 1993; Lusky and Fontane, 1991; Santucci et 
al., 1990; Sun et al., 1990; Thorner et al., 1988; Thorner et al., 1993; Ustav et 
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al., 1991; Wilson and Ludes-Meyers, 1991). El has also DNA-dependent 
ATPase activity, DNA helicase activity and it can serve to unwind the origin of 
replication (MacPherson et al., 1994; Seo et al., 1993b; Yang et al., 1993). In 
addition, the El protein is able to associate with the large subunit of cellular 
DNA polymerase a (Bonne-Andrea et al., 1995b; Park et al., 1994), bind to 
70 kD subunit of cellular RPA complex (Han et al., 1999) and interact with a 
key cell cycle regulator of S phase, the cyclin E-Cdk2 kinase (Cueille et al., 
1998). The El protein can interact specifically with the viral E2 protein in 
solution (Blitz and Laimins, 1991; Mohr et al., 1990) and on the ori (Benson 
and Howley, 1995; Lusky and Fontane, 1991; Sarafi and McBride, 1995; 
Sedman and Stenlund, 1995). This interaction results in co-operative binding of 
El and E2 to the origin of replication (Gillette et al., 1994; Gillette and 
Borowiec, 1998; Sedman and Stenlund, 1995; Seo et al., 1993a; Spalholz et al., 
1993; Yang et al., 1991a). El by itself binds to the ori with a low degree of 
sequence specificity, in the presence of E2 the sequence specificity is increased 
(Sedman and Stenlund, 1995; Sedman et al., 1997). In this process, E2 
functions transiently and "catalytically", providing sequence specificity for the 
formation of an El-ori complex (Gillette and Borowiec, 1998; Lusky et al., 
1994; Sanders and Stenlund, 1998; Sedman and Stenlund, 1995; Sedman and 
Stenlund, 1996; Sedman et al, 1997). The formation of an replication-
competent initiation complex is a two-step process where the first step involves 
the binding of El and E2 to ori and the second step involves the assembly of 
additional El molecules onto this complex and the displacement of E2 in a 
process that requires ATP hyrdolysis (Sanders and Stenlund, 1998). In the El-
ori complex, the El protein forms a DNA-dependent hexameric complex (Fouts 
et al., 1999; Sedman and Stenlund, 1998), which is able to unwind DNA bi-
directionally from the ori site and therefore is likely to represent an early step in 
the initiation of DNA replication. 
2.4. The papillomavirus E2 proteins 
The viral E2 protein is the master regulator of the viral life cycle — this protein 
modulates the transcription of viral genes, is responsible for the initiation of 
viral DNA replication and for the stable maintenance of the viral genome. The 
BPV1 E2 ORF encodes three proteins: a 48 kD full-length E2 transactivator 
(E2TA) and two transcriptional repressors, E2C and E8/E2 with molecular 
masses of 30 and 28 kD, respectivaly (Haugen et al., 1987; Hirochika et al., 
1987; Hubbert et al., 1988; Spalholz et al., 1985). 
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Figure 2. The structure of the three BPV1 E2 proteins are shown at the top of the 
figure. Below, the functions that have been mapped to different regions of the proteins 
are indicated. 
E2 proteins localize in the nucleus of the cell (Burnett et al., 1990; Hubbert et 
al., 1988; Skiadopoulos and McBride, 1996) and a large amount of the full-
length E2 protein is associated with insoluble chromatin and nuclear matrix 
components (Hubbert et al., 1988). Two different basic regions have been 
suggested to function as nuclear localization signals (NLS) in the full-length E2 
protein (Skiadopoulos and McBride, 1996). The NLS in C-terminus of BPV1 
E2, positioned within residues 339 and 352 (BR3, KCYRFRVKKNHRHR), 
which contains the DNA recognition helix of the DNA binding domain has 
been found to mediate the transport of the protein to the nucleus (Allikas et al., 
2000; Skiadopoulos and McBride, 1996). The point-mutation in the second, the 
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amino-terminal NLS (BR2, aa 107 to 115, KRCFKKGAR) causes re-localization 
of the protein into the cytoplasm, but also induces the aggregation and oligome-
rization of E2 (Abroi et al., 1996). Recent studies have revealed that in addition 
to diffuse nuclear localization, some part of E2 together with El is localized in 
intranuclear domains, called ND 10 or POD (promyelocytic oncogenic do­
mains) (Swindle et al., 1999) or is transported there by viral L2 protein (Day et 
al., 1998). These foci are proposed to be DNA replication compartments and 
sites of papillomavirus assembly. 
BPV1 E2 protein is phosphorylated in mammalian cells. Five phosphory­
lation sites (aa 235, 277, 290, 298, 301) in the hinge region of the protein are 
mapped (Lehman et al., 1997; McBride et al., 1989). In transient assays, 
phosphorylation site mutants of E2 are normal for transcriptional activation and 
DNA replication; the genome replicated even to higher levels than the wild-
type. But phosphorylation site mutants of E2 are severly crippled for function(s) 
required for viral plasmid retention and oncogenic transformation (Lehman et 
al., 1997; McBride et al., 1989). Recent data show that segregation of viral 
plasmids during cell division is regulated by phosphorylation (Lehman and 
Botchan, 1998). 
2.4.1. Structural and functional domains of the E2 protein 
The 410 amino acid BPV1 E2 protein is composed of relatively well-defined 
function-specific modules. Structural and mutational analyses have revealed 
three distinct domains. The amino-terminal part (residues 1 to 210) is an activa­
tion domain for transcription and replication. It is followed by the unstructured 
hinge region and the carboxy-terminal DNA-binding-dimerization domain 
(DBD)(residues 310 to 410) (Giri and Yaniv, 1988; Haugen et al., 1988; 
McBride et al., 1989; McBride etal., 1988). 
The N-terminal transactivation domain of E2 (TAD) has a very high struc­
tural integrity, as any deletion that has been made within this domain inactivates 
all the protein functions. (Haugen et al., 1988; Winokur and McBride, 1992; 
Winokur and McBride, 1996). Even a single amino-acid substitution can easily 
inactivate the protein (Abroi et al., 1996; Brokaw et al., 1996; Ferguson and 
Botchan, 1996; Grossei et al., 1996). Computer predictions of secondary struc­
ture of the TAD of E2 reveal that this domain begins with two amphipathic a-
helices, the rest of the domain is mainly composed of small hydrophobic ß-
sheets (Abroi et al., 1996; Giri and Yaniv, 1988). In 1999, the crystal structure 
of the protease-resistant core (residues 66 to 215) of the HPV 18 E2 activation 
domain was published (Harris and Botchan, 1999). This reveals a fold creating 
a cashew-shaped form with a glutamine-rich a helix packed against a ß-sheet 
framework. Residues 106-190 form a core structure of the activation domain, 
this is a novel ß-sheet framework where is an intricate layering of ß strands that 
are relatively bowed or briefly disrupted as they transition between alternate 
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sheets. Various E2 proteins average 30% amino acid sequence identity and 
papillomavirus E2 proteins show some functional conservation, for instance, 
combinations of intertypic El and E2 genes can complement each other for 
viral replication (Berg and Stenlund, 1997; Chiang et al., 1992) and mutational 
analyses on BPV1, HPV 16 and HPV 11 E2 genes have shown consistent results. 
These results suggest that various E2 activation domains share a common fold. 
When joined to a DNA binding domain, the N-terminal 194 amino acids of 
BPV1 E2 are able to activate transcription from an E2-responsive promoter 
(Winokur and McBride, 1992). The results from our lab indicate that the N-
terminal residues 1-192 form a structural and functional activation domain of 
the BPV 1 E2 protein for replication, when this domain is anchored to DNA via 
heterologous DNA binding domain (Allikas et al., 2000). The mutational ana­
lyses of the activation domain of E2 show that the determinants responsible for 
activation of replication and transcripition are partially separable (Abroi et al., 
1996; Brokaw et al., 1996; Ferguson and Botchan, 1996; Grossei et al., 1996). 
However, a single critical region required for transcription have not identified, 
inactivating mutants are dispersed throughout the transactivation domain. Some 
transcriptional activation-defective mutants (R37,173, E74) retain the ability to 
cooperate with El in viral replication (Ferguson and Botchan, 1996; Grossei et 
al., 1996) and to support replication (Abroi et al., 1996), whereas the E2 mutant 
E39 reduced replication activity but left transcriptional activation intact 
(Ferguson and Botchan, 1996). 
The carboxy-terminal 85 aa of BPV1 E2 (aa 326 to 410) are sufficient for 
sequence-specific DNA binding and dimerization (Corina et al., 1993; Dostatni 
et al., 1988; Lambert et al., 1987; McBride et al., 1989; McBride et al., 1988; 
Prakash et al., 1992). A high-resolution crystal structure for the minimal core 
region complexed with DNA revealed that the DNA-binding domain is folded 
into a dimeric ß-barrel. Across the surface of the barrel, each E2 monomer 
contributes a short a helix (aa 336 to 344) which lies in the major groove of 
DNA, making specific contacts with the DNA (Hegde et al., 1992; Hegde et al., 
1998). Later it was shown that aa 311-325 are also important for stability and 
integrity of C-terminal DNA-binding-dimerization domain as this region 
influences the DNA-binding affinity and protein stability (Pepinsky et al., 1997) 
and that the effect is mediated through intramolecular interactions between the 
flanking region and the core domain (Vee*araghavan et al., 1998). The residues 
which make direct contacts with DNA are N336, K339, C340, F343 and R344 
(Hegde et al., 1992). A highly conserved cysteine residue at position 340 is very 
sensitive to oxidation (McBride et al., 1992). The DNA binding domain of the 
E2 proteins forms a stable dimer even in the absence of DNA (Corina et al., 
1993; McBride et al., 1989). Dimers of E2 are highly resistant to urea 
denaturation (Corina et al., 1993). The DNA binding and dimerization pro­
perties of this domain cannot be separated by deletion analysis; all deletions that 
have been tested eliminate both properties of the C-terminal domain. A highly 
conserved tryptophan residue at position 360 has been designated to form the 
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tryptophan bridge (Corina et al., 1993). Mutated E2 proteins containing hydro­
phobic residues at this position are functional but substitution of W360 by polar 
residues disrupts dimerization. 
The amino-terminal activation and carboxy-terminal DNA-binding-dimeri-
zation domains are separated by hinge region of approximately 100 residues. 
There has been found no sequence conservation in the hinge region among 
different papillomavirus E2 proteins, despite conservation in the DNA binding 
and activation domains. This may indicate that the hinge regions of the E2 
proteins do not carry the conserved function. Several studies have indicated that 
hinge region of the BPV1 E2 may be involved in the regulation of the E2 
protein activity through interaction with transcription factors (Ham et al., 1994) 
and could be important for replication (Kurg et al., 1999; Winokur and 
McBride, 1992). Our recent work demonstrates that some critical length and 
flexibility, but not the particular amino acid sequence of the hinge region is 
required for the ability of E2 to bind to DNA and to initiate DNA replication 
from the minimal-origin-containing plasmid in transient assay (Allikas et al., 
2000). However, the hinge region of E2 is required for stable plasmid main­
tenance; it is needed for chromatin attachment of the viral genome as it contains 
phosphorylation sites of the BPV1 E2 protein (Lehman and Botchan, 1998). 
Analyses of mutations in the E2 ORF which delete various regions of the E2 
protein have revealed that, in most cases, an intact transactivation domain and 
an intact DNA-binding-dimerization domain are required for transcription, and 
for El-E2-ori complex formation as well as for the initiation of replication. 
Large deletions in the hinge region affect mostly DNA binding and replication, 
but less transcription (Allikas et al., 2000; Winokur and McBride, 1992; 
Winokur and McBride, 1996). 
2.4.2. E2 DNA-binding sites 
The dimeric E2 protein binds specifically to the 12-bp palindromic sequence 
ACC(N6)GGT (Androphy et al., 1987; Dostatni et al., 1988; Moskaluk and 
Bastia, 1987; Moskaluk and Bastia, 1988b). These sites are located throughout 
papillomavirus genome but are particularly concentrated within the URR 
(Harrison et al., 1987; Hawley-Nelson et al., 1988; Spalholz et al., 1988; Spal­
holz et al., 1987). BPV1 has 12 sites that correspond to this sequence and 
additional five closely related sequences that can also bind E2 (Li et al., 1989). 
Equilibrium and kinetic studies show that the range of E2 affinities of these 
17 sites vary over 300-fold (Li et al., 1989). The higher affinity sites are 
clustered in the URR in regions called E2-dependent enhancer elements E2RE1 
and E2RE2 (Spalholz et al., 1987). A low level of E2-dependent activation can 
be obtained with one E2 binding motif, however, two E2 DNA-binding sites co­
operate to constitute a strong enhancer (Lambert et al., 1989a; Morrissey et al., 
1989; Stanway et al., 1989; Thierry et al., 1990; Spalholz et al., 1987). Some 
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co-operativity in DNA binding has been observed in vitro, the region 
responsible for this co-operativity is encoded by the N-terminal part of the 
protein (Monini et al., 1993; Monini et al., 1991; Thierry et al., 1990). DNA-
bound E2 molecules have been demonstrated to associate and form stable DNA 
loops visible by electron microscopy (Knight et al., 1991). E2TA binds co­
operatively to two adjacent DNA binding sites with a cooperativity parameter of 
8.5, while the 86 aa DNA binding domain and the E2C protein exhibit much 
less cooperativity (factors 1.9 and 2.9, respectively) (Monini et al., 1991). 
Genomic footprinting have shown that in vivo E2 binds DNA molecules that 
contain one, two or three E2BS-S even in the absence of transcriptional acti­
vation (Lefebvre et al., 1997). 
The BPV1 E2 proteins bind to DNA with high affinities which have been 
measured in the range of 2 x 10~10 to 2 x 10_11M (Li et al., 1989; Monini et al., 
1993; Monini et al., 1991). The precise contact points of the E2 protein on the 
ACC(N6)GGT motif have been determined (Hegde et al., 1992; Hines et al., 
1998; Moskaluk and Bastia, 1988b; Rozenberg et al., 1998). According to the 
crystallographic data, the base pairs GGT are the region of greatest contact with 
the protein recognition helix. The nucleotides in the non-conserved core and 
immediately outside the binding site determine the affinity for the E2 protein. 
The sequence-specific DNA binding is often accompanied by deformation of 
the DNA. The DNA within the E2/E2BS complex adopts ~43°C bend towards 
the minor groove at the center of the target (Hegde et al., 1992; Moskaluk and 
Bastia, 1988a) and recently it has been shown that BPV E2 protein binding 
affinity depends on DNA flexibility (Hines et al., 1998; Rozenberg et al., 1998). 
E2 binding can be inhibited by CpG methylation of the ACCGN4CGGT motif 
(Thain et al., 1996)(M. Ustav, unpublished data). 
2.4.3. The E2 protein as a transcription factor 
The BPV l E2 protein, functioning through E2 binding sites, regulates the 
transcription of the early viral genes (McBride et al., 1991; Spalholz et al., 
1985). E2 can also activate heterologous promoters when its binding sites are 
cloned either upstream or downstream of the transcription initiation site 
(Gauthier et al., 1991; Hawley-Nelson et al., 1988; Thierry et al., 1990). E2 can 
act either as a repressor or an activator of transcription depending on the 
position of its binding sites relative to the promoter sequence (Dostatni et al., 
1991). For instance, E2TA can also repress transcription when the E2 motifs are 
situated close to the transcriptional start site, overlapping the binding sites for 
essential cellular transcription factors (Stenlund and Botchan, 1990; Vande Pol 
and Howley, 1990). E2 has also an ability to activate several heterologous 
promoters which lack E2BS in transient assay, albeit to much lesser extent 
(Haugen et al., 1987). The E2 protein stimulates transactivation probably by 
direct or indirect interactions with some components of the basic transcriptional 
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machinery. E2 is unable to activate minimal promoters containing only a TATA 
box but requires additional promoter proximal elements such as Spl (Ham et 
al., 1991; Ushikai et al., 1994). E2 interacts with basal transcription factors, 
including Spl (Li et ai, 1991; Ushikai et al., 1994), TBP (TATA-binding 
protein) (Dostatni et al., 1991; Ham et al., 1994; Rank and Lambert, 1995; 
Steger et al., 1995) and TFEB (Benson et al., 1997; Rank and Lambert, 1995; 
Yao et al., 1998). The activation domain modulating factor (AMF-1) has also 
been shown to associate with the BPV1 E2 (Breiding et al., 1997) and E2 co­
operatively stimulates transcription with cellular transcription factors USF and 
CTF (Ham et al., 1991; Ushikai et al., 1994). BPV1 E2 can also transactivate 
promoters containing E2 binding sites in Saccharomyces cerevisiae (Lambert et 
al., 1989a; Morrissey et al., 1989; Stanway et al., 1989) indicating that inter­
actions of E2 with transcription machinery are well conserved. Furthermore, the 
in vitro interaction between in Saccharomyces cerevisiae TFXIB and E2 has 
been demonstrated (Benson et al., 1997). Both the N-terminal transactivation 
domain (Benson et al., 1997; Yao et al., 1998) and the C-terminal DNA-
binding-dimerization domain of E2 (Rank and Lambert, 1995) interact with 
TFIIB. However, the E2 transactivation domain itself can stimulate transcrip­
tion in eukaryotic cells when cloned onto a heterologous DNA-binding domain 
(Breiding et al., 1996; Winokur and McBride, 1996). The BPV E2 protein can 
substitute for cellular enhancer binding factors in initiation of Polyomavirus 
DNA replication, if the enhancer region is replaced by binding sites for the E2 
protein (Nilsson et al., 1991) (A.Abroi; unpublished results). In addition, the 
binding of transcriptionally competent E2 to two or three tandem binding sites 
but not to a single site modifies the chromatin structure around the promoter 
(Lefebvre et al., 1997; Li and Botchan, 1994). 
2.4.4. The E2 protein as a replication factor 
The E2 protein is the master regulator of extrachromosomal replication of 
papillomaviruses (for review (Ustav and Ustav, 1998)). The E2 protein facili­
tates binding of the viral helicase El to the origin of replication (Lusky et al., 
1994; Sedman and Stenlund, 1995; Sedman et al., 1997). In this process, E2 
functions transiently and "catalytically", providing sequence specificity for the 
formation of an El-ori complex (Gillette and Borowiec, 1998; Lusky et al., 
1994; Sanders and Stenlund, 1998; Sedman and Stenlund, 1995; Sedman and 
Stenlund, 1996; Sedman et al., 1997). A direct interaction between the viral E2 
and El proteins has been demonstrated in solution as well as on the ori (Blitz 
and Laimins, 1991; Lusky and Fontane, 1991; Mohr et al., 1990; Sarafi and 
McBride, 1995), this interaction is mediated through the amino-terminus of the 
E2 protein (Benson and Howley, 1995; Berg and Stenlund, 1997; Winokur and 
McBride, 1996). In the yeast two hybrid system, the first 91 amino acids of E2 
were able to interact with the El protein (Benson and Howley, 1995). Berg and 
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Stenlund have demonstrated that BPV 1 E2 DNA-binding-dimerization domain 
is also independently capable of interacting with El when the El and E2 
binding sites are adjacent to each other (Berg and Stenlund, 1997). However, 
the E2C protein is unable to interact with or cooperatively bind to the origin 
with the El protein (Mohr et al., 1990; Winokur and McBride, 1996). The 
activation domain of E2, fused to the DNA-binding domain of either yeast 
transcription factor GCN4 or EBNA1 of Epstein-Barr virus, is shown to be 
sufficient for initiation of replication (Berg and Stenlund, 1997; Kivimäe et al., 
2000). The BPV1 and HPV-11 E2 activation domains are equally capable of 
interacting with BPV El and to support replication (Berg and Stenlund, 1997). 
This indicates that the replication functions of these proteins are quite well 
conserved. In addition, E2 has also shown to facilitate the single-stranded DNA-
binding protein A (RPA) to interact with the ori (Li and Botchan, 1993). 
2.4.5. The other activities of the E2 protein 
The BPV1 E2 is necessary for long-term episomal maintenance of viral geno­
mes within replicating cells (Piirsoo et al., 1996). Recent studies have shown 
that the BPV genome is attached to mitotic chromosomes (Lehman and 
Botchan, 1998; Skiadopoulos and McBride, 1998) and that this association is 
mediated by the viral E2 protein (lives et al., 1999; Lehman and Botchan, 1998; 
Skiadopoulos and McBride, 1998). The N-terminal transactivation domain of 
E2 is shown to be crucial for the chromatin attachment activity (Skiadopoulos 
and McBride, 1998; Lehman and Botchan, 1998; lives et al., 1999). Lehman 
and Botchan suggest that the hinge region between the N- and C-terminal 
domains, which includes the major phoshorylation sites of the E2 protein, is 
also important for the attachment (Lehman and Botchan, 1998). Ilves and co­
workers suggest that the E2 protein in trans and its multiple binding sites in eis 
are both necessary and sufficient for the chromatin attachment of the plasmid 
(lives et al., 1999). 
The expression of BPV 1 E2 results in growth inhibition of HeLa and other 
HPV-positive cell lines (Desaintes et al., 1997; Desaintes et al., 1999; Dowha-
nick et al., 1995; Goodwin et al., 1998; Hwang et al., 1993). An intact transacti­
vation and DNA-binding-dimerization domains are required for growth sup­
pression (Desaintes et al., 1997; Dowhanick et al., 1995; Goodwin et al., 1998). 
It has been suggested that E2 represses the endogenous E6 transcription and this 
causes accumulation of a transcriptionally active p53 (Desaintes et al., 1997; 
Dowhanick et al., 1995; Hwang et al., 1993). However, recent data suggest that 
E2-induced apoptosis is an early event, independent of p53 accumulation and 
unrelated to downstream p53-dependent transcriptional events and that E2 is 
able to activate also p53-independent growth-inhibitory signals (Desaintes et 
al., 1999; Goodwin et al., 1998). 
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3. RESULTS AND DISCUSSION 
As described in review of literature, the BPV 1 E2 protein is the master regulator 
of the papillomavirus replication and transcription, the activity of which is 
regulated through sequence-specific DNA binding. The E2 protein consists of 
three function-specific domains. The N-terminal part (residues 1 to 210) is an 
activation domain for transcription and replication, it is followed by the hinge 
region and the C-terminal DNA-binding — dimerization domain (residues 310 
to 410) (Giri and Yaniv, 1988; Haugen et al., 1988; McBride et al., 1989; 
McBride et al., 1988). The transactivation domain of E2 is the only part of the 
protein, which is specifically required for both, replication and transcription 
activities (Winokur and McBride, 1996, Berg and Stenlund, 1997); it is shown 
to interact with several replication and transcription proteins (Sections 2.4.3 and 
2.4.4). More information about the structure of this domain and of the whole 
protein is needed to understand better how the functioning of E2 in replication 
and transcription is achieved. The crystal structure of the full-length BPV 1 E2 
protein is not yet determined and we have to rely on other methods to examine 
the structural organization of the whole protein and the molecular interactions 
that must occur to accomplish the activity of the protein. To study the structure-
function relationship of the E2 protein we have used two different approaches. 
First, point-mutations within the transactivation domain of E2 were made to 
determine regions important for the transcription and replication functions and 
second, monoclonal antibodies were produced and used as probes and tools to 
study the structure and function of the protein. 
The El and E2 proteins are required for the initiation of DNA replication 
from the papillomavirus origin (Ustav and Stenlund, 1991). The viral DNA 
replication origin contains an El binding site flanked by E2 binding sites (Ustav 
et al., 1991). The El and E2 proteins interact to form a protein complex and 
bind cooperatively to the origin of replication (Gillette et al., 1994; Gillette and 
Borowiec, 1998; Sedman and Stenlund, 1995; Seo et ai, 1993a; Spalholz et al., 
1993; Yang et al., 1991a). Formation of the replication preinitiation complex 
requires specific protein-protein and protein-DNA interactions between the El 
and E2 proteins and their respective DNA binding motifs. We wanted to 
determine is it possible to inhibit papillomavirus DNA replication by preventing 
binding of the E2 protein to its recognition sequence. Again, two different ways 
were used: first, monoclonal antibody against the E2 DBD was used to inhibit 
E2 binding to DNA and second, E2BS was blocked by PNA to hide the E2 
recognition sequence. 
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3.1. Mutational analysis of the BPV1 E2 protein 
(Reference I) 
In order to determine regions within the transactivation domain of E2, which are 
important for the transcription and replication function, a set of mutant E2 
proteins was constructed. Single conserved charged residues in the amino-
terminal transactivation domain of E2 were replaced with alanine. These mutant 
E2 proteins were tested for expression and for transcriptional and replicational 
activation in functional assays. The mutational analysis of the activation domain 
of E2 showed that the transcription and replication activities of E2 are partially 
separable and are encoded by different determinants in the E2 protein. 
Transcription activation defective mutants, which retained their ability to 
support replication, were R37A, E74A, E90A, D122A and D143A/R172C. E2 
mutants Kl 11A, Kl 12A and E176A were defective in both assays (I, Fig. 4). 
Some years ago not much was known about the structure of the activation 
domain of E2 and point-mutations were made according to computer pre­
dictions only (Fig. 3). In 1999, the crystal structure of the protease-resistant core 
(residues 66 to 215) of the HPV 18 E2 activation domain was published (Harris 
and Botchan, 1999). According to these data, residues 106-190 form a core 
structure of the activation domain, this is a ß-sheet framework built of antiparal-
lel strands, flexible loops that connect the strands are generally exposed at the 
edges of the core of the protein (Harris and Botchan, 1999). Based on the 
crystallographic data of HPV 18 E2, a protein model of the same fragment of 
BPV1 E2 (Fig. 4) was made using the SWISS-MODEL service (Peitsch, 1995; 
Peitsch, 1996). In the present thesis I have used this theoretical protein model to 
analyze the E2 mutants, which were made based on computer predictions only. 
Transcription-defective but replication competent E2 mutants E90A and D122A 
fell in the loop regions of core structure of activation domain and residue E74 is 
involved in the long NH2-terminal a helix (Fig. 4D). All these residues are 
exposed on the surface of the core structure of the activation domain of E2. So, 
they can, in principle, be involved in interactions with transcription machinery 
of the cell. These results also showed that there is no single critical region re­
quired for transcription, inactivating mutants were dispersed throughout the 
transactivation domain. However, mutations I73A and Q76A by others (Fergu­
son and Botchan, 1996; Harris and Botchan, 1999; Sakai et al., 1996) induced 
proteins with the same phenotype and this a helix surface is probably important 
in transcriptional activation. Transcription-defective but replication competent 
mutant proteins R37A, E90A and D122A localized in the nucleus of the cell 
and existed in the dimeric form, however, in the case of mutations E74A and 
D143A/R172C only part of the protein existed as a dimer able to form a specific 
E2-DNA complex. Our futher studies indicated that mutation E74A caused also 
formation of oligomers, including tetramers, which were stable enough to be 
separated from the dimeric form of E2 by the glycerol gradient centrifugation. 
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We have proposed that amino terminus-mediated oligomerization could also 
serve as a mechanism for the regulation of E2 biological activity. 
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Figure 3. Positions of the point-mutations in the transactivation domain of the E2 
protein. (I) The prediction of secondary structure (cylinder, a-helix; arrows, ß-sheets) 
made by Rost and Sander (Rost and Sander, 1993). (II) The secondary structure of the 
protease resistant core of the BPV1 E2 based on the crystallographic data of the 
HPV 18 E2. 
Substitutions Kill A, K112A and E176A in the transactivation domain of E2 
resulted in inactive proteins in both, transcription and replication assays and 
caused re-localization of E2 from the nucleus into the cytoplasm of the cell. 
These mutants were also unable to form an E2-DNA complex of the usual size; 
however, considerable retention of the probe in wells was detected (I, Fig. AC). 
Glycerol gradient sedimentation analysis showed that mutations in the positions 
of Kill, K112 and E176 induced conformations of the proteins, which were 
able to oligomerize and aggregate. The pronase treatment of inactive mutant 
Kill A, K112A and E176A proteins showed that their DNA binding abilities 
were readily present in the proteins, they were only masked due to aggregation. 
So, we concluded that these mutations probably disrupted the conformation of 
the transactivation domain, which lead to aggregation of the E2 protein and that 
the oligomerization and aggregation of the protein resulted in their inactivity in 
all functional assays. On the structural model of the activation domain of BPV 1 
E2 protein, E2 residues Kill and K112 lie within the ß sheet A and are 
involved in the formation of the core structure of E2 activation domain. Amino 
acid E176 lies on the inner edge of the main cavity and is involved in a short a 
helix within the core structure of the activation domain. Therefore all these 
three amino acids are necessary for functionally active conformation of the 
activation domain of E2. K111A and K112A fell in the region (residues 107 to 
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Figure 4. Structure of the protease-resistant core of the BPV1 E2 modelled by SWISS-
MODEL service (Peitsch, 1995; Peitsch, 1996) according to the crystallographic data of 
the protease resistant core of the HPV18 E2 (Harris and Botchan, 1999). (A) The mole­
cule is coloured by protein secondary structure: a-helixes are coloured red, ß-sheets yel­
low, turns are blue and others white. (B) Ribbon diagram rotated 90 degrees around the 
x axis to show the pattern of ß-sheets. (C) Ribbon diagram rotated 180 degrees around 
the y axis. (D) Location of transcription-defective but replication competent E2 mutants 
is shown on the ribbon diagram of protease-resistant core of E2. (E) Location of inactive 
E2 mutants Kl 11 A, Kl 12A and E176A on the core structure of the activation domain of 
the E2 protein. 
115), which has been identified as a potentional NLS for E2, however, this 
sequence is not able to mediate active transport of a hybrid protein into the 
nucleus (Skiadopoulos and McBride, 1996). As aa Kill is not exposed on the 
surface of the protein and K112 is involved in charge interactions with the 
acidic side chain of E90 (Harris and Botchan, 1999), therefore it is unlikely that 
they can act in the transport of the protein to the nucleus proposed by 
Skiadolopous and McBride (Skiadopoulos and McBride, 1996). So, our 
conclusion that localization of mutant proteins to cytoplasm was caused rather 
by aggregation of the proteins than by a mutation in NLS, was correct and is 
consistent with the crystallographic data. In summary, mutations, which fell into 
ß sheet or a helix of the core structure of the activation domain of E2 
influenced the functionally active conformation of the protein and resulted in 
inactive proteins in sequence-specific DNA binding as well as in transcription 
and replication. Mutations, which fell in the loop regions of core structure, 
maintained the structure of the domain and were able to exist in dimeric form. 
In conclusion, our work showed that the activation domain of E2 has a 
discrete disruptable structure, which is very sensitive to point-mutations. Later, 
this suggestion has been confirmed by crystallographic data (Harris and 
Botchan, 1999). In several studies (Abroi et al., 1996; Brokaw et al., 1996; 
Cooper et al., 1998; Ferguson and Botchan, 1996; Grossei et al., 1996; Sakai et 
al., 1996), amino acid substitutions have been generated in the transactivation 
domains of the BPV1, HPV 11 and HPV 16 E2 proteins to determine which 
regions of this domain are important for the transcription and replication 
functions. Among these studies, we were the only one who showed that 
sometimes the point-mutation can also disrupt the conformation of the protein 
and how difficult it may be by simple loss-of-function assays to discern those 
residues of E2 that may be interacting specifically with other cellular or viral 
partners. 
3.2. Monoclonal antibodies against the BPV1 E2 protein 
(Reference II) 
In this study, we have produced and characterized a panel of monoclonal anti­
bodies (MAbs) as probes and tools for studying the structure and function of the 
BPV1 protein. 
First, the BPV1 E2 protein was expressed in E.coli and purified by con­
ventional chromatography. This purified functionally active protein was used to 
immunize the mice. A total of 22 MAbs that were reactive to the E2 protein in 
an enzyme immunoassay were isolated. Seventeen of these MAbs were directed 
against linear epitopes and were mapped within the region between amino acids 
180-309 of E2. In fact, the last part of the amino-terminal transactivation 
domain and the first 10 amino acids of the hinge region, residues 180 to 218, 
appear to constitute highly immunogenic "hot spot", since epitopes for 12 of 
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these 17 MAbs were found to be localized within this region. All MAbs against 
the linear epitopes, with the exception of 1E2, were able to recognize the DNA-
bound E2 protein. Epitopes for 5 of the 22 MAbs were mapped within the C-
terminal DNA-binding-dimerization domain. All of these antibodies recognized 
the composite epitopes of native E2 and did not react with the denatured E2 
protein (II, Fig. 2). None of the epitopes for the MAbs tested were mapped to 
the first 180 residues of the E2 protein. When only a purified transactivation 
domain, containing residues 1 to 208, of E2 was used for immunization, four 
MAbs against the region between aa 1 and 180 of E2 were obtained; however 
none of them was able to recognize E2-DNA complex in a mobility shift assay 
(A.Abroi, unpublished results). The most antigenic regions are usually the less 
ordered regions of the protein, and thus the antigenicity could be, to some 
extent, a reflection of the structure. So, we concluded from these results that in a 
native context, both the transactivation domain and the DNA binding-
dimerization domain of E2 have a complex and relatively rigid structure, while 
the central, hinge region is highly mobile and flexible. This conclusion is 
supported by crystallographic data of C-terminal DNA-binding-dimerization 
domain of BPV1 E2 (Hegde et al., 1992) and of the protease-resistant core 
(residues 66 to 215) of the HPV 18 E2 activation domain (Harris and Botchan, 
1999), which show that both of these domains are tightly packed. In addition, a 
study of the HPV 16 E2 protein has shown that the hinge is an unstructured 
region (Gauthier et al., 1991). Polyclonal antibodies were generated against 
overlapping peptides covering the entire E2 protein and it was found that only 
antibodies against the hinge region could recognize the native, undenatured E2 
protein. 
MAb 1E2 (epitope within residues 184 to 190) was able to recognize neither 
E2-DNA nor El-E2-ori complex in a mobility shift assay. Curiously, deletion 
of the first a helix from the BPV1 E2 protein revealed the epitope for MAb 
1E2, and protein in the E2-DNA complex was recognized by the antibody (II, 
Fig. 2C). We suggested that the epitope for this MAb is probably buried within 
the compact structure of the N-terminal domain and is not accessible unless the 
structure of the molecule is distorted in some fashion. According to crystallo­
graphic data (Harris and Botchan, 1999), epitope for Mab 1E2 (TGHYSVR) is 
exposed on the surface of the protease resistant core (aa 66-215) of the protein. 
This epitope is situating on the opposite side of the protein comparing to the 
first a helix of the crystallized fragment of the protein. As the first 65 amino 
acids are not involved in the crystal structure of the protease resistant core of 
the activation domain of E2, it is difficult to say how are the first two 
amphipatic a helixes placed and are they able to hinder the epitope for MAb 
1E2 or not. 
The observation that antibodies recognized their respective epitopes in the 
DNA-bound E2 protein raised, the possibility that some of them are able to 
block the E2 protein functions in the initiation of BPV1 origin replication. 
Therefore, the purified antibodies were tested in the transient replication assay. 
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MAb 5H4, directed against the C-terminal DBD prevented efficiently the 
formation of E2-DNA as well as El-E2-origin complexes and also dissociated 
preformed complexes in a concentration-dependent manner (II, Fig. 3A, 5A). 
Co-transfection of MAb 5H4 with BPV1 minimal origin containing plasmid 
pUCAlu into CHO 4.15 cells resulted in a dose-dependent inhibition of 
replication (II, Fig.4A). The Fab' fragment of MAb 5H4 was also capable of 
dissociating the preformed E2-DNA complex and able to inhibit BPV1 origin 
replication (II, Fig. 5). So, we were able to suppress the papillomavirus origin 
replication by preventing E2 binding to its recognition sequence. This is a new 
and very specific way to demonstrate that the BPV 1 E2 protein interaction with 
the specific recognition sequence within an origin of replication is essential for 
the initiation of viral DNA replication. 
MAb 3F12 and MAbs 1H10 and 1E4, directed against the hinge region, 
recognized their respective E2 epitopes in the El-E2-origin complex (II, Fig. 
3A). At the same time they were capable of inhibiting BPV1 origin replication 
in CHO 4.15 cells (II, Fig. 4). However, the Fab' fragments of 1H10 and 3F12 
had no effect in the transient replication assay (II, Fig. 5). These data suggested 
that MAbs directed against the hinge region sterically hinder the inter- or 
intramolecular interactions required for the replication activity of the E2 
protein. We concluded that the conformational freedom of the E2 protein is 
important for its role in replication, the MAbs probably would not allow E2 to 
assume the proper conformation required for its replication activity. It has been 
shown that E2 proteins with deletions of the entire hinge region (E2A220-309 and 
E2A2i2-309) were unable to support replication (Winokur and McBride, 1992), 
but could efficiently enhance the binding of El to the replication origin 
(Winokur and McBride, 1996). So, we can suggest that some sequence is 
required between the two conserved domains to maintain some other function of 
E2, in addition to El binding, required for the replicational activity of the 
protein. Further studies in our lab have indicated that some critical length and 
flexibility, but not the particular amino acid sequence of the hinge region, is 
required for the ability of E2 to bind to DNA and to support replication in 
transient assay (Allikas et al., 2000). 
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3.3. Inhibition of the BPV1 E2 protein activity by PNA 
(Reference III) 
PNA-s are oligonucleotide analogues in which the deoxyribose phosphate 
backbone is replaced by non-charged N-(2-aminoethyl)glycine polymer (Niel­
sen et al, 1991). The ability of PNA to associate with high affinity to comple­
mentary ssDNA, RNA and dsDNA (Demidov et al., 1995; Egholm et al., 1993; 
Peffer et al., 1993) and, additionally, very high stability of PNA polymers in 
biological systems (Demidov et al., 1994), makes this new class of biopolymers 
very attractive as a potential candidate for therapeutics. In the present study we 
have investigated if the specific peptide nucleic acid (PNA) is able to interfere 
with E2 binding to DNA. 
First, we demonstrate that PNA can specifically associate with the E2BS by 
forming the complex with dsDNA. In vitro binding experiments using a 
radiolabeled E2BS demonstrated that binding of PNA to duplex DNA was 
sequence specific and salt-dependent, and preceding separation of DNA strands 
and linearization of PNA enhanced the formation of PNA-DNA complex in 
vitro (III, Fig.3). Stable PNA-DNA complexes have so far been demonstrated 
mostly for homopyrimidine PNA-s binding to homopurine targets. We showed 
that PNA is able to form a stable and specific complex with dsDNA of mixed 
sequence. The PNA bound to the dsDNA with sufficient affinity to specifically 
prevent binding of the E2 protein to its target site (III, Fig. 4). However, PNA 
was able to inhibit E2 binding in vitro under certain conditions. We were not 
able to demonstrate specific activity when the PNA binding was performed in 
E2 binding buffer, which had a KCl concentration of lOOmM. Specific activity 
was observed when PNA was incubated with the DNA target in low salt buffer 
(TE) prior to addition to the E2 binding buffer. In this case, binding of PNA to 
its duplex target correlated with inhibition of E2 binding. 
Next we looked at the ability of PNA to block the E2 protein dependent 
BPV 1 origin replication by inhibiting E2 binding to its target site. Our aim was 
to block the E2BS within the origin of replication with PNA and to inhibit in 
this way the formation of replication initiation complex. In a cell culture model, 
specific inhibition was observed when PNA was incubated with origin 
containing plasmids in buffer with low salt concentration prior to electropora-
tion. BS9-specific PNA bound effectively to Ori construct Mspl5BS9 and 
resulted in the inhibition of replication. In the case of papillomavirus minimal 
origin plasmid pUCAlu, which contains E2BS11 and E2BS12, a weak binding 
of PNA was observed. But binding of PNA to both E2BS with low efficiency 
resulted in strong inhibitory effect in replication assay (III, Fig. 5). So, partial 
blocking of both E2BS within an origin of replication resulted in synergistic 
response of viral DNA replication. However, we were not able to detect any 
specific inhibitory effect when PNA was mixed with the plasmid pUCAlu and 
electroporated into the cells without pre-forming PNA-plasmid complex. 
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In summary, in this study we were able to suppress the E2 protein dependent 
BPV1 origin replication by blocking the E2BS with PNA and as a result, 
inhibiting E2 binding to its target site. This is another way to demonstrate that 
E2BS within an origin of replication is necessary and the BPV1 E2 protein 
interaction with the specific recognition sequence within an origin of replication 
is essential for the initiation of viral DNA replication. 
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4. CONCLUSIONS 
1. The activation domain of the E2 protein has a discrete disruptable structure, 
which is sensitive to point-mutations. Substitutions Kill A, K112A and 
E176A in the transactivation domain of E2 disrupted the conformation of the 
domain and induced oligomerization and aggregation of the protein, which 
resulted in their inactivity in replication and transcription and caused re-
localization of E2 from the nucleus into the cytoplasm of the cell. 
2. In a native context, both the transactivation domain and the DNA-binding-
dimerization domain of BPV 1 E2 have a complex and rigid structure, while 
the central, hinge region, is highly mobile and flexible. This conclusion is 
based on the immunogenic properties of the E2 protein. 17 of the 22 mono­
clonal antibodies obtained were directed against linear epitopes within the 
hinge region. Epitopes for 5 of the 22 MAbs were mapped within the C-
terminal DBD and these antibodies recognized only the composite epitopes. 
In addition, MAbs against the hinge region and DBD but not against the acti­
vation domain were able to recognize the native form of the BPV1 E2 
protein. 
3. The flexibility of the hinge region is important for the replication activity of 
the E2 protein. MAb 3F12 and MAbs 1H10 and 1E4, directed against the 
hinge region, were capable of inhibiting BPV 1 origin replication, while the 
Fab' fragments of 1H10 and 3F12 had no effect in the transient replication 
assay. We suggest that MAbs directed against the hinge region sterically 
hinder the inter- or intramolecular interactions required for the replicational 
activity of the E2 protein. 
4. The BPV1 E2 protein interaction with the specific recognition sequence 
within an origin of replication is essential for the initiation of viral DNA 
replication in vivo. We were able to suppress the E2 protein dependent BPV 1 
origin replication by inhibiting E2 binding to its recognition sequence. The 
inhibition of replication was achieved in two different ways: first by MAb 
and Fab' 5H4, which prevented efficiently the formation of E2-DNA as well 
as El-E2-origin complexes and second, by PNA, which blocked the E2BS 
within the origin of replication. 
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STRUCTURE-FUNCTION RELATIONSHIP 
OF THE BOVINE PAPILLOMAVIRUS 
E2 PROTEIN 
Summary 
The papillomaviruses are small DNA viruses that induce squamous epithelial 
proliferative lesions (warts) in their natural hosts. The papillomavirus life cycle 
is greatly regulated by the viral transcription factor E2. This protein regulates 
viral protein levels by modulating the transcription of viral genes, is responsible 
for initiation of DNA replication and for the stable maintenance of the viral 
genome, which is achieved through facilitiation of the association of the viral 
genome with chromatin. E2 is a sequence-specific DNA-binding protein; it 
consists of three function-specific domains. The N-terminal part is an activation 
domain for transcription and replication, it is followed by the hinge region and 
the C-terminal DNA-binding dimerization domain. In this work, we have shown 
that in a native context, both the transactivation domain and the DNA-binding 
dimerization domain of BPV 1 E2 have a complex and rigid structure, while the 
central, hinge region, is highly mobile and flexible. The activation domain of 
the E2 protein has a discrete disruptable structure, which is sensitive to point-
mutations. Mutations in the transactivation domain of E2 disrupted the con­
formation of the domain and induced oligomerization and aggregation of the 
protein, which resulted in their inactivity in replication and transcription and 
caused re-localization of E2 from the nucleus into the cytoplasm of the cell. We 
also showed, that the flexibility of the hinge region is important for the repli­
cation activity of the E2 protein. In addition, we demonstrate that the BPV1 E2 
protein interaction with the specific recognition sequence within an origin of 
replication is essential for the initiation of viral DNA replication in vivo. We 
were able to suppress the E2 protein dependent BPV1 origin replication by 
inhibiting E2 binding to its recognition sequence. The inhibition of replication 
was achieved in two different ways: first by MAb and Fab' 5H4, which pre­
vented efficiently the formation of E2-DNA as well as El-E2-origin complexes 
and second, by PNA, which blocked the E2BS within the origin of replication. 
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VEISE PAPILLOOMI VIIRUSE VALGU E2 
STRUKTUURI JA FUNKTSIOONI SEOS 
Kokkuvõte 
Papilloomiviirused on väikesed kaheahelalised DNA-viirused, mis tekitavad 
oma peremeesorganismidel soolatüükaid ja muid epiteelkoe vohandeid. Papil-
loomiviiruse elutsüklis etendab keskset rolli viiruse transaktivaatorvalk E2. See 
reguleerib transkriptsiooniks, replikatsiooniks ja transformatsiooniks vajalike 
viirusevalkude ekspressiooni rakus. Samuti on E2 vajalik viiruse DNA replikat­
siooniks ja viiruse genoomi pikaajaliseks säilimiseks rakus. E2 on DNA-
seoseline valkja seega reguleerib tema aktiivsust võime seonduda DNA-le. 
Käesolevate teeside esimeses pooles antakse ülevaade veise papilloomi-
viiruse gerioomist, geeniekspressioonist, transkriptsioonist ja replikatsioonist. 
Eraldi alapeatükid on pühendatud veise papilloomiviirusevalgu E2 omadustele 
ja funktsioonidele. Kolmandas peatükis on lühidalt kokku võetud käesoleva töö 
aluseks olevate publikatsioonide sisu. 
Käesoleva doktoritöö peamised tulemused on järgmised. 
Viirusevalk E2 koosneb kolmest domeenist: transkriptsiooniks ja replikat­
siooniks vajalik aktivatsioonidomeen, DNA-seostumis- ja dimerisatsioonido-
meen ja neid lahutav "hinge"regioon. E2 aktivatsioonidomeeni suunatud punkt-
mutatsioonanalüüs näitas, et muteerides mõnda valgu konformatsioonile olulist 
aminohapet, rikutakse ära valgu funktsionaalse struktuur ning selle tulemusena 
on täheldatav E2-valgu oligomeriseerumine ja agregeerumine. Agregeerunud 
valk on inalktiivne ega suuda täita oma rolli viiruse transkriptsioonil ja replikat-
sioonil. Meie katsed näitavad ka, et E2 aktivatsiooni- ja DNA-seostumisdomeen 
on mõlemad jäiga struktuuriga ja korrektselt pakitud, kuid neid lahutav "hinge"-
piirkond liikuv ja struktureerimata. Kasutades monokloonseid antikehasid, näi­
tasime, et E2 hingepiirkond on samuti vajalik valgu aktiivsuseks replikatsioonis. 
Viiruse DNA replikatsiooniks rakkudes on vajalikud kaks viirusevalku: 
replikatsiooni initsiaatorvalk El ja transaktivaatorvalk E2. Replikatsiooni init­
sieerimiseks peavad El ja E2 mõlemad seostuma replikatsiooni alguskohaga, 
kusjuures E2 roll on kaasa aidata El järjestusspetsiifilisele seostumisele. Käes­
olevates töödes on õnnestunud inhibeerida E2-st sõltuvat DNA replikatsiooni, 
blokeerides E2 seostumist tema sidumisjärjestusele. Esimesel korral kasutasime 
selleks monokloonset antikeha, mis takistas valgu seostumist tema sidumis­
järjestusele, teisel korral blokeerisime E2 sidumisjärjestuse replikatsiooni 
alguspunktis PNA-ga (peptiidne nukleiinhape). 
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A set of G2 proteins with mutations in the amino-terminal transactivation domain was made by a scheme 
called clustered charged-to-alanine scan. These mutant E2 proteins were tested for expression, stability, and 
compartmentalization in cells and for sequence-specific DNA binding, as well as in functional assays for 
transcriptional and replicational activation. We identified four groups of mutants. First, mutants K111A, 
K112A, and E176A were unable to activate replication and transcription because of oligomerization-induced 
retention of oligomers in the cytoplasm. Second, although fractions of the mutant proteins E74A and D143A/ 
R172C existed in the oligomeric form, they were localized in the nucleus. Certain fractions of these proteins 
existed as a dimer able to form a specific complex and activate replication; however, these proteins were 
inactive in transcriptional activation. Third, mutants R37A and D122A were localized in the nucleus, existed 
in the dimeric form, supported replication efficiently, and were severely crippled in transcriptional activation. 
The fourth group of mutants did not differ considerably from the wild-type protein. The activation of tran­
scription by the wild type as well as mutant E2 proteins was dependent on the concentration of input E2 
expression vector DNA and had a bell-like shape. We suggest that the reduction of transcriptional activation 
at higher E2 concentrations, the self-squelching activity, is caused by oligomerization of the E2 transactivator 
and is one of the mechanisms for the regulation of E2 activity. Our results also show that transcriptional and 
replicational activation activities are encoded by different determinants in the E2 protein. 
Transcriptional activators modulate the activity of the basal 
transcription machinery in eukaryotic cells, and they function 
at the assembly stage of the transcription initiation complex or 
stimulate the formation of the elongation complex (for re­
views, see references 30 and 61). In addition, transcription 
factors are frequently involved in the modulation of DNA 
replication (for a review, see reference 12). Small DNA vi­
ruses, like papillomaviruses, provide a useful model system to 
study the functional and structural determinants of transcrip­
tion factors involved in the regulation of transcription and 
replication. The 48-kDa full-length E2 protein of bovine pap­
illomavirus type 1 (BPV1) was identified as a typical eukaryotic 
transcription activator, with all the properties of such proteins, 
including modular DNA binding and activation domains and 
the ability to activate heterologous promoters from DNA bind­
ing sites at a distance from the transcription start site. It has 
been demonstrated previously that E2 binding sites function 
synergistically in vivo and mediate E2-dependent induction of 
the expression of viral early genes of papillomaviruses (19, 21, 
47, 51, 52, 60). That fact served initially as an explanation for 
the involvement of the E2 protein in the regulation of viral 
DNA replication as a transcriptional activator of the expres­
sion of viral early genes (13, 38). Later, however, it was shown 
that E2 protein directly participates in the replication process 
of viral DNA during each of the three stages of the viral life 
cycle. First, after the initial entry of the viral genome into the 
nucleus of the cell, papillomavirus DNA is amplified, i.e., pap-
* Corresponding author. Mailing address: Department of Microbiol­
ogy and Virology, Institute of Molecular and Cell Biology, Tartu 
University, Estonian Biocentre, 23 Riia St., EE2400 Tartu, Estonia. 
Phone: 372 7 420 223. Fax: 372 7 420 286. Electronic mail address: 
ustav@ebc.ee. 
illomavirus DNA replicates faster than does cellular DNA 
(27). The El and E2 proteins are the only viral factors used for 
the initiation of DNA replication from the papillomavirus or­
igin at this amplification stage of the viral life cycle (9, 40, 56, 
57, 59). The minimal origin of replication has been identified 
as the essential eis element in this process and consists of three 
sufficient and necessary elements, an AT-rich region, El bind­
ing site, and E2 binding site (55). The second stage of the virus 
life cycle, the latent replication, is established when the optimal 
copy number of the viral genome is achieved. The establish­
ment of stable extrachromosomal replication of the BPV1 ge­
nome requires at least six E2 binding sites in eis and El and E2 
proteins in trans, in addition to the minimal origin (37). During 
the third stage, the vegetative stage of the papillomavirus life 
cycle, DNA amplification is initiated in terminally differenti­
ated keratinocytes. It has been suggested that the E2 protein is 
directly involved in the regulation of this process (8). There­
fore, the E2 protein is the master regulator of viral gene ex­
pression as well as all the stages of viral DNA replication. 
Structural and mutational analyses of the E2 protein have 
revealed three distinct functional domains. The N-terminal 
part (residues 1 to 210) is an activation domain for transcrip­
tion and replication. It is followed by the unstructured hinge 
region (residues 210 to 324) and the carboxy-terminal DNA 
binding-dimerization domain (residues 325 to 410) (15,19, 31, 
32). The structure of the carboxy-terminal DNA binding-
dimerization domain has been solved by X-ray analysis and has 
revealed a novel dimeric DNA binding-dimerization motif 
(20). A similar organization of a DNA binding-dimerization 
domain has been determined for Epstein-Barr virus nuclear 
antigen 1 (5). However, very little, except for computer pre­
dictions, is known about the structural organizations and prop­
erties of the hinge region and the amino-terminal transactiva-
13 
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tion domain of the E2 protein. The dimeric E2 protein binds 
an interrupted palindromic sequence, ACC(N0)GGT; dimers 
are stable and highly resistant to urea denaturation; and a 
small 85-residue protease-resistant C-terminal core domain 
retains the ability to bind DNA (10, 14). E2 binding sites 
function synergistically in vivo because of cooperativity in the 
binding of E2 to clustered binding sites, which is mediated via 
the amino-terminal transactivation domain (35, 52). E2 is able 
to loop DNA when E2 binding sites are widely spaced on the 
template (22). The E2 protein binds multiple proteins, includ­
ing cellular replication protein A, papillomavirus replication 
protein El, ccllular transcription activator Spl, and basal tran­
scription factors TATA-binding protein (TBP) and TFIIB (4, 
25, 26, 28, 34, 39, 50). Spl and El are known to bind the N 
terminus of E2, while TBP and TFIIB interact with the C-
terminal part of the E2 molecule. Very little, though, is known 
about the structural determinants of E2 involved in the direct 
interactions with these or other proteins. To identify structur­
ally and functionally important determinants within the E2 
protein, a number of deletion and in-frame insertion mutations 
have been made (13, 19, 58). The majority of these mutations 
abolished the replication and transcriptional activities of the 
E2 protein. These studies indicate that the E2 DNA binding-
dimerization domain, in addition to the intact transactivation 
domain, is needed for this protein to function in replication 
and transcriptional activation. However, it was not determined 
which E2 mutations disrupt its activity directly and which in­
hibit E2 function indirectly by interfering with the DNA bind­
ing or stability of the E2 protein. 
Here we characterize 15 different mutant E2 proteins with 
point mutations within the transactivation domain. These mu­
tations were designed by a scheme called clustered charged-
to-alanine scan (11). Analyses of these mutants showed that 
the structural determinants responsible for the transcriptional 
activation function in the E2 protein could genetically be sep­
arated from the structural determinants responsible for the 
activation of replication. In addition, our data indicate that 
oligomerization of the E2 protein mediated by the N-terminal 
transactivation domain could be one of the additional mecha­
nisms regulating the activities of this protein in transcription 
and replication. 
MATERIALS AND METHODS 
Plasmids. El expression vector pCGEag, E2 expression vector pCGE2, and 
replication reporter pUCAlu have been described previously (56). Reporter 
Plasmids pP2CAT and pSV3BS9CAT were kind gifts of Paul Szymanski. Plasmid 
pSV3BS9CAT contains three E2 high-affinity binding sites (binding site 9 [BS9J), 
three 21-bp GC-rich repeats, and an enhancerless simian virus 40 (SV40) early 
promoter (nucleotides 5172 to 103 from SV40) in front of the chloramphenicol 
acetyltransferase (CAT) gene. Plasmid pP2CAT contains BPVI nucleotides 7476 
to 94 (including the P2 promoter) in front of the CAT gene. Plasmid p53:E2 was 
generated by substituting the E2 transactivation domain for the p53 transactiva­
tion domain (amino acids 1 to 58) by using Xbal and Seal restriction sites in 
pCGE2epi (55) (see Fig. 1A). Plasmid VP16:E2 has been described previously 
(25) and contains 80 C-terminal amino acids from VP16 fused to the C terminus 
of E2 (starting from amino acid 250) in the context of pCG. 
To generate mutant E2 proteins, the Xbal-Kpnl fragment from pCGE2 was 
cloned into pUC19. E2 protein mutants were created by the PCR-based method 
of Mikaelian and Sergeant and then inserted back into pCGE2 at the Xbal-Kpnl 
sites (33). All mutants were verified by sequencing. The introduced mutations at 
the nucleic acid and protein levels are presented in Table 1. 
Cells and transfections. Transient-replication assays were carried out as de­
scribed by Ustav and Stenlund (56). CHO cells were electroporated with 100 ng 
of pUCAlu DNA, 500 ng of pCGEag, and 250 ng of wild-type or mutant pCGE2. 
Replication assays were quantitated with a Phosphorlmager SI (Molecular Dy­
namics). For transcription assays, CHO cells were electroporated with 250 ng of 
the respective reporter and various amounts of pCGE2 or derivatives. Forty 
hours later, cells were harvested and lysed by freezing-thawing, and CAT assays 
were performed by the thin-layer chromatography method in the linear range 
(43). The acetylated form of chloramphenicol was quantitated with a liquid 
scintillation counter. Activities were normalized to the total amount of protein in 
TABLE 1. Generated point mutations in the E2 coding sequence 
Starling 
position 
Codon 
Wild type Mutated" 
Change at the 
amino acid 
level 
Name of 
mutant 
2641 CAA GCA Gln-12—>Ala Q12A 
2644 GAA GCA Glu-13—»Ala E13A 
2665 GAG GCG Glu-20—»Ala E20A 
2716 AGA GCA Arg-37-»Ala R37A 
2722 GAG GCG Glu-39—»Ala E39A 
2746 AGG GCG Arg-47—»Ala R47A 
2809 AGA GCA Arg-68-»Ala R68A 
2827 GAA GCA Glu-74—»Ala E74A 
2875 GAA GCA Glu-90->Ala E90A 
2938 AAG GCG Lys-Ul—»Ala K111A 
2941 AAA GCA Lys-112->Ala K112A 
2971 GAT GCT Asp-122-»Ala D122A 
3034 GAC GCC Asp-143-»Ala D143A 
3133 GAG GCG Glu-176—»Ala E176A 
3121 CGC TGC Arg-172—»Cys R172C 
" Mutated nucleotides are in bold letters. 
the lysate, as determined by the Bradford assay (6). The values shown are the 
averages of at least three independent transfection experiments. 
DNA binding assay. For the preparation of COS-7 extracts, cells transfected by 
electroporation with expression plasmids were removed from the semiconfluent 
100-mm-diameter plates with a rubber policeman, washed, and lysed in 100 fil of 
lysis buffer (50 mM Tris-HCI, pH 7.5, 100 mM KCl, 0.1 mM EDTA, 0.35% 
Nonidet P-40, 10 mM dithiothreitol, and protease inhibitors) on ice for 30 min. 
The cell debris was removed by centrifugation, glycerol was added to a final 
concentration of 20%, and the extracts were aliquoted and stored at —70°C. The 
amounts of E2 protein in cell extracts were determined by enzyme-linked im­
munosorbent assay (ELISA) using bacterially expressed E2 protein as a stan­
dard. Equal amounts of lysates containing E2 mutant proteins were used in DNA 
binding assays. For gel shifts, respective amounts of cell extracts were incubated 
in 10 p.! of binding buffer (10 mM Tris-HCI, pH 7.5, 100 mM KCl, 2 mM 
dithiothreitol, 0,5 mM phenylmethylsulfonyl fluoride, 15% glycerol, 5 mg of 
bovine scrum albumin [BSA] per ml, 1 jig of leupeptin per ml, 1 ng of aprotinin 
per ml) at room temperature for 15 min in the presence of 1 p,g of sonicated 
salmon sperm DNA and 0.2 ng of end-labeled probe. The double-stranded 
high-affinity BS9 of BPV1 (5'-ACAAAGTACCGTTGCCGGTCGAA-3') was 
used as a probe. Protein-DNA complexes were separated from unbound DNA 
on 6% PAAG (80:1) in 0.25X Tris-borate-EDTA. Gels were dried and exposed 
to X-ray film. Quantitative analysis was done with a Phosphorlmager SI (Mo­
lecular Dynamics). For pronase digestion experiments, increasing amounts of 
pronase were added; the reaction mixtures were incubated for an additional 10 
min at room temperature before or after DNA binding, loaded onto a Polyacryl­
amide gel, and processed as described above. 
Immunoblotting of E2. Comparisons of the expression levels and estimations 
of the intactness of E2 mutant proteins in COS-7 and CHO cells were done by 
Western blot (immunoblot) analysis using rabbit anti-E2 polyclonal antibody. 
Cells from a semiconfluent 60-mm-diameter dish were lysed 36 h after electro­
poration in 200 |j.l of Laemmli sample buffer and boiled for 10 min, and Western 
blotting was done as previously described (18). In addition, COS-7 cell extracts 
prepared for the DNA binding assay were also tested for the concentration of E2 
protein by immunoblotting. 
Glycerol density-gradient centrifugation. Extracts (100 p.1) of COS-7 cells 
transfected with E2 or mutants were layered on the top of 5-ml linear glycerol 
gradients (10 to 30%; 10 mM Tris-HCI, pH 7.6, 0.1 mM EDTA, 100 mM NaCl, 
1 mM dithiothreitol, and protease inhibitors). The samples were centrifuged in 
a Beckman SW55 rotor at 45,000 rpm for 15 h at 4°C. Marker proteins, alcohol 
dehydrogenase (150 kDa), and BSA (66 kDa) were run in parallel gradients. The 
gradient was dripped into 14 fractions, and the bottom of the tube was washed 
with 250 fil of buffer containing 10% glycerol. Collected fractions were subjected 
to quantitative ELISA analysis and sequence-specific gel shift assay. The final 
wash was done with 50 jj.1 of Laemmli buffer in order to solubilize the precipi­
tated protein, which was then subjected to sodium dodecyl sulfate (SDS)-PAAG 
and Western blot analysis with monoclonal antibody 1E2 (epitope, amino acids 
180 to 190). 
Immunofluorescence. For immunofluorescence analysis, COS-7 cells were 
transfected by electroporation with 150 ng of E2 expression vector pCGE2. After 
that, cells were allowed to adhere to coverslips, grown for 48 h, and fixed in cold 
(-20°C) acetone-methanol (1:1) for 10 min. Coverslips were washed three times 
with phosphate-buffered saline (PBS), and primary antibody was added at a 
concentration of 10 ng/|tl (diluted in PBS containing I jig of BSA per jxl). 
Coverslips were incubated for 1 h at room temperature and washed three times 
with PBS, and fluorescein isothiocyanate-conjugated goat anti-mouse secondary 
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FIG. 1. (A) Schematic representations of designed H2 point mutations and 
chimeric E2 proteins. The prediction of the secondary structure (cylinder, alpha-
helix; shaded box, ß-sheet) was made by the method of Rost and Sander for the 
N-terminal part of the E2 molecule (41). The structure of the C-terminal part of 
the E2 protein is presented according to the X-ray structure (20). The locations 
of mutations are indicated by arrows. (B) Immunoblot analysis of the expression 
of E2 proteins in CHO cells. Cell lysates were prepared from cells transfected 
with a wild-type (WT) or mutant E2 expression plasmid. Thirty microliters of cell 
lysate was loaded in each lane. The negative (neg) control lysatc was prepared 
from cells electroporated with carrier DNA only. The mutant used is indicated 
above each lane. 
antibody (Sigma) was added at the concentration recommended by the manu­
facturer. After 1 h, coverslips were washed three times with PBS and mounted on 
glass slides in 50% glycerol. Cells were examined on a Olympus Vanox-S AH2 
microscope. Monoclonal antibody 3F12 (epitope, amino acids 199 to 207) was 
used as the primary antibody. 
RESULTS 
data indicated that the constructed mutant proteins were sta­
ble and expressed at approximately the same level. 
The activities of mutants in transient-replication assays. 
We used two different origin-containing plasmids (pUCAlu 
and pP2CAT) in transient-replication assays with CHO cells to 
study the abilities of E2 mutants to activate replication. The 
expression plasmid for mutant E2 proteins was cotransfected 
with the origin plasmid and El expression vector pCGEag into 
CHO cells by electroporation, and episomal DNA was ex­
tracted by alkaline lysis, purified, digested with Dpnl and lin­
earizing enzyme, and analyzed by Southern blotting as de­
scribed earlier (56) (Fig. 2). All mutant E2 proteins, except for 
Kill A, K112A, and E176A (Fig. 2, lanes 21 to 24, 31, and 
32), supported the replication of origin-containing plasmid 
pUCAlu in CHO cells in the transient-replication assay. Sim­
ilar results were obtained with origin-containing plasmid 
pP2CAT (data not shown). Eight independent replication as­
says were quantitated and normalized to wild-type E2 protein 
activities (see Fig. 4B). Two mutants, R37A and E90A, seem to 
be up-mutations and activate the replication of the BPV1 or­
igin 1.6 and 2.2 times better, respectively, than does the wild-
type protein. 
The activities of E2 mutants in transcriptional activation of 
promoters. It has been shown that different promoters can be 
activated to different extents by the BPV1 E2 protein, depend­
ing on the promoter content (17,54). The activities of mutants 
were tested in CAT assays using two different E2-dependent 
reporter plasmids. Plasmid pP2CAT contains the BPV1 URR 
and the native P2 promoter, including the transcription initia­
tion site (nucleotide 89), Reporter plasmid pSV3BS9CAT con­
tains an SV40 early promoter in which the 72-bp enhancer is 
replaced by three E2 binding sites (BS9) in front of the basal 
promoter driving the CAT coding sequence (Fig. 3A). The 
reporter plasmid either alone or with increasing amounts of 
the E2 expression vector was transfected by electroporation 
into CHO cells. Forty hours later, the extracts were prepared 
for CAT assays (43). The CAT activities in the extracts of cells 
transfected with mutant E2 proteins were normalized to the 
basal activity without added E2 expression plasmid and to the 
total amount of protein. We tested the transactivation function 
of all mutants at various concentrations of transfected expres­
sion vectors (0.0004 to 3 |ig of DNA per 7 X 106 cells). We 
observed that the level of activation of promoters by wild-type 
E2 and E2 mutants was dependent on the amount of the input 
DNA of the E2 expression vector (Fig. 3B to E). The extracts 
of cells transfected with expression constructs for E2 mutants 
E74A, Kill A, K112A, E176A, and D143A/R172C showed 
Expression of mutant proteins. To identify the structural 
and functional determinants of the E2 protein involved in the 
activation of transcription and/or replication functions, a set of 
mutant E2 proteins was constructed. Single conserved charged 
residues in the amino-terminal transactivation domain were 
replaced with alanine. The introduced point mutations are 
described in Fig. 1A on the putative secondary structure of the 
E2 protein and summarized in Table 1 (41). We used two 
different cell lines (CHO and COS-7) to test the stabilities and 
expression levels of mutant proteins in vivo. The expression 
vector was delivered into cells by a standard electroporation 
procedure (56), cells were lysed, and the expression level and 
stability of each mutant protein were tested by ELISA and 
Western blot analysis. All mutant E2 proteins were expressed 
at similar levels compared with the wild-type E2 protein in 
CHO (Fig. IB) and COS-7 (data not shown) cells. No degra­
dation of mutant proteins in the cell lysate was observed. These 
FIG. 2. The abilities of mutant E2 proteins to activate the replication of the 
BPV1 origin in CHO cells. Cells were electroporated with 100 ng of reporter 
plasmid pUCAlu, 500 ng of pCGEag, and 250 ng of pCGE2, which expresses 
wild-type (wt) E2 or derivatives. Cells were harvested either 36 or 48 h ( /J ) 
after electroporation. Episomal DNA was digested with Dpnl and linearizing en­
zyme Hindlil and analyzed by Southern blotting. 
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FIG. 3. (A) Structures of the reporter plasmids used in transcription and replication activation assays. The numbers indicate positions in the BPV1 URR sequences. 
(B to E) Transcription activation assays with E2 protein mutants. CHO cells were transfected with increasing amounts of the expression vector for E2 mutants or 
chimeric E2 proteins, as indicated, and with 250 ng of reporter plasmid pSV3BS9CAT. Normalized CAT activities were determined 40 h after transfcction. The symbol 
for each mutant proteins is indicated in the corresponding panel. (B) Mutants with nearly wild-type protein properties in transcription activation assays. (C) Mutant 
proteins whose transcriptional activities have decreased to approximately 50% of that of the wild-type protein. (D) Inactive mutant proteins. (E) Transcriptional 
activation properties of chimeric proteins p53:E2 and VP16;E2. 
essentially basal levels of CAT activity, independent of the 
amount of input E2 expression vector, with pSV3BS9CAT 
(Fig. 3D) or pP2CAT reporters (data not shown). In the case 
of active mutants, the optimal concentration of E2 expression 
vector was within 80 to 100 ng of pCGE2 DNA per transfection 
and resulted in activation of more than 30 times the basal level 
(Fig. 3B to E). In all cases, higher-than-optimal E2 concentra­
tions resulted in a reduction in transactivation (Fig. 3B and C), 
most likely caused by the self-squelching activity of E2. This 
activity for the E2 protein has been described previously, and 
the mechanism for this is unknown (39). The suppression of 
activation at higher E2 concentrations is specific for the E2 
transactivation domain because it is not observed for p53:E2 
and VP16:E2 chimerical proteins, in which the E2 transactiva­
tion domain is replaced by the activation domains of p53 and 
VP16, respectively (Fig. 3E). The expression levels of wild-type 
and hybrid p53:E2 and VP16:E2 proteins in CHO cells were 
comparable (data not shown). 
The activities of R37A, D122A, and D143A were dependent 
on the promoter context of the reporter plasmid used. Point 
mutations R37A and D122A (Fig. 3C and 4B) resulted in a 
sharp decrease in transactivation to 20% of that of the wild-
type protein from reporter pSV3BS9CAT; however, with 
pP2CAT as the reporter, these mutants were moderately active 
(Fig. 4B). In the case of D143A, the same tendency was ob­
served; however, the corresponding relative activities were 
higher. The third group of mutants (Q12A, R68A, and E90A) 
were 50% active with both reporters compared with wild-type 
E2. 
The results described above show that point mutations 
K111A, K112A, and E176A create proteins inactive for both 
functions, transcriptional and replicational activation. E2 pro-
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FIG. 4. (A) DNA binding assay with mutated E2 proteins. The sequence-spccific binding of E2 to one DNA palindromic target was determined by ge! retardation 
assays. The E2 proteins were expressed in COS-7 cells. Band shift assays were performed with 2 ul of cell extract and 0.5 ng of radiolabeled BS9 for 15 min at room 
temperature. Protein-DNA complexes were resolved on 6% PAAG in 0.25X Tris-boratc-EDTA. oligo, oligonucleotide; wt, wild type. (B) Comparison of the activation 
of transcription from two reporter plasmids, replication, and DNA binding abilities of E2 protein mutants. The radioactive signals of gel shift and replication assays 
were quantitated with a Phosphorlmager. The wild-type (WT) E2-specific signal in all assays was set at 1.0. For transcription activation assays, CHO cells were 
electroporated with 250 ng of the indicated reporter and 250 ng of pCGE2 or a derivative. Normalized CAT activities were determined 40 h after transfection. In all 
cases, the values shov/n are the results (± standard errore) of at least three independent transfection experiments. (C) Pronase treatment of lysates containing inactive 
E2 mutant proteins. The reaction mixtures were incubated first with 0.2 or 2 (ig of pronase for 10 min at room temperature and then with labeled BS9 for an additional 
10 min. Protein-DNA complexes were resolved on 8% PAAG in 0.25X Tris-borate-EDTA. DBD, DNA binding domain. 
tein mutants E74A and D143A/R172C were crippled in the 
transcriptional activation function but were competent to sup­
port replication in the transient-replication assay. E2 protein 
mutants R37A and D122A were also defective in transcrip­
tional activation, though this defect was less obvious in the case 
of the P2 promoter. These data may indicate that the replica­
tion and transcriptional transactivation functions of the BPV1 
E2 protein are encoded at least in part by separate determi­
nants. 
The activities of mutant E2 proteins in sequence-specific 
DNA binding. Sequence-specific DNA binding is essential for 
the expression of most of the functional activities of the E2 
protein. Therefore, we decided to study the activities of mutant 
E2 proteins in sequence-specific DNA binding assays, even 
though mutations were made in the N-terminal transactivation 
domain of this protein. The expression vector pCG allows 
high-level expression of the cloned cDNA in COS cells, which 
makes the quantitation of the concentrations of mutant E2 
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proteins in lysates by ELISA more accurate. The expression 
levels of the E2 protein and mutants in CHO cells were suffi­
cient for the detection of specific gel shift; however, they were 
difficult to measure by quantitative ELISA using the standard 
curve obtained with bacterially expressed E2 protein. In addi­
tion, the expression levels of wild-type and mutant E2 proteins 
were sufficient for the separation of lysates in the glycerol 
gradient to establish the physical oligomerization status of E2 
mutants. The lysates of transfected COS-7 cells were tested 
for the ability to form an E2-specific complex with double-
stranded high-affinity BS9 (5'-ACAAAGTACCGTTGCCGG 
TCGAA-3') of the BPV1 E2 responsive element (E2RE1) by 
quantitative gel shift assay. Lysates obtained by the sonication 
of cells or by the use of 0.35% nonionic detergent Nonidet P-40 
gave essentially the same results in gel shift assays. The shifted 
double band was specific for E2, as it was supershifted by 
anti-E2 monoclonal antibody 3F12 (epitope, residues 199 to 
207) and was inhibited by an excess of the nonlabeled specific 
oligonucleotide (data not shown) (23). The cloned E2 open 
reading frame carried a mutation from the initiating methio­
nine (codon ATG) to isoleucine (codon ATC) in the E2 tran­
scription repressor and was unable to express the repressor 
form of E2. Therefore, the appearance of the lower band is not 
caused by the shorter repressor form of the E2 protein. A 
similar gel shift pattern has been observed in several instances 
for baculovirus-, yeast-, or bacterium-expressed E2 protein and 
probably reflects a different conformation of the complex (23, 
35, 50). Equal amounts of lysates of cells containing wild-type 
and mutant E2 proteins were used in the binding reaction 
mixtures, and complexes were separated in a standard gel shift 
assay. Our data indicate that most of the E2 mutants had 
approximately the same or, in some cases, even better ability to 
bind DNA (Fig. 4A); however, E2 mutants with point muta­
tions Kill A, Kl 12A, and E176A, which were inactive for both 
replication and transcription, failed to form the specific pro-
tein-DNA complex able to enter the gel. These data indicate 
that mutations K111A, K112A, and E176A seem to abolish the 
DNA binding abilities of these proteins and therefore the 
functioning of the E2 protein in transcription and replication, 
or to induce the formation of E2 protein oligomers or aggre­
gates unable to enter the gel. Mutants E74A and D143A/ 
R172C showed reduced affinity in the DNA binding assay (50 
and 30%, respectively, from the wild-type level). The carboxy-
terminal part of the E2 protein is responsible for DNA binding 
and contains a protease-resistant core (14). In order to test 
whether introduced mutations Kill A, K112A, and E176A de­
stroyed the total folding of the E2 protein, including the DNA 
binding domain, induced a protein conformation inactive for 
interaction with DNA, or resulted in a protein with high-level 
oligomerization-aggregation properties, we subjected the ly­
sates to pronase treatment. Pronase treatment of the lysates of 
cells transfected with K111A, K112A, or E176A revealed the 
E2-specific DNA binding activities of these mutants (Fig. 4C). 
The same results were obtained when the extracts were treated 
with protease either before or after the addition of DNA to the 
binding reaction mixture. These data indicate that the point 
mutations introduced into the amino-terminal part of the mol­
ecule did not destroy overall folding of the E2 protein, but 
some other mechanism prevented the formation of an E2-
DNA complex of the usual size. We also observed that the 
trapping of a specific DNA probe in a gel well, especially in the 
case of Kl IIA, K112A, and E176A mutants, disappeared upon 
treatment with pronase. 
One interesting group consisted of E2 mutants which were 
able to support DNA replication at the wild-type level in the 
transient-replication assay but had severely reduced transcrip-
J. VIROI.. 
FIG. 5. The localization of E2 mutant proteins in COS-7 cells by immuno­
fluorescence analysis. COS-7 cells were transfected with carrier DNA (A), 
pCGE2-wt (B), pCGE2 K111A (C), pCGE2 K112A (D), and pCGE2 E176A 
(E). Cells were probed with monoclonal antibody against the E2 protein and 
subsequently with fluorescein isothiocyanate-conjugated anti-mouse antibody as 
described in Materials and Methods. 
tional activities. E2 mutants with point mutations R37A and 
D122A bound DNA as well as wild-type E2 did; however, 
E74A and specifically D143A/R172C bound DNA at reduced 
levels (Fig. 4A). Again, considerable entrapment of the specific 
probe could be detected in wells. 
DNA binding activities were quantitated with a Phosphor­
lmager and normalized to the binding activity level of ex­
pressed wild-type E2 protein. The results, DNA binding to­
gether with the activities of mutant proteins to activate 
transcription from the two different reporter constructs and 
quantitation of the replication data, are shown in Fig. 4B. 
These results confirm earlier observations that the DNA bind­
ing ability of E2 is absolutely required for specific transcrip­
tional activation. Furthermore, these data indicate that the 
transcription activation domain of the E2 protein has consid­
erable impact on the regulation of the functioning of this 
protein. 
Compartmentalizatioa of mutant proteins in COS-7 cells. 
The E2 transactivator contains three regions which can consti ­
tute a potential nuclear localization signal for this protein, BR1 
(residues 47 to 49), BR2 (residues 107 to 115), and BR3 (res­
idues 340 to 353). It has been shown that only BR3 is able to 
mediate active transport of a hybrid protein (ß-galactosidase) 
into the nucleus; however, BR2 has been suggested to work as 
the major nuclear localization signal of E2TA. Partial or com­
plete deletion of this sequence or a proline-to-glycine mutation 
at residue 106 causes mutant proteins to accumulate in the 
cytoplasm (46). Two such mutations, Kill A and K112A, were 
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made in the BR2 region, therefore raising the possibility that 
the inactivity of these mutants in biological assays is caused by 
the failure of this protein to enter the nucleus. We studied the 
nuclear localization of all mutant proteins in COS-7 and CI 27 
cells. The localization of E2 mutants in COS-7 cells is pre­
sented in Fig. 5. We used mouse monoclonal antibody 3F12, 
directed against the epitope within residues 199 to 207, for the 
detection of the E2 protein. Essentially, the same results were 
obtained when another monoclonal antibody, 3C1 (residues 
280 to 310), or polyclonal rabbit immunoglobulin G against the 
E2 protein was used in these experiments (data not shown). 
Figure 5A and B show the immunostaining of COS-7 cells 
transfected with a mock and wild-type E2 expression construct, 
respectively. We detected specific exclusive nuclear immuno­
staining in cells expressing wild-type E2 protein compared with 
mock-transfected cells. Contrary to wild-type E2, mutant pro­
teins K111A (Fig. 5C), K112A (Fig. 5D), and E176A (Fig. 5E) 
are preferentially localized in the cytoplasm, with very little, if 
any, detectable specific immunostaining in the nucleus. All the 
remaining mutant proteins were localized in the cell nucleus 
(data not shown). 
Oligomerization of mutant proteins. The expression levels 
of all mutant proteins in CHO (Fig. IB) and COS-7 cells were 
comparable, as estimated by Western blotting of the total cell 
extract and soluble cell extract used for gel shift analysis. In the 
case of mutants K111 A, K112A, and E176A, we were unable to 
detect the formation of a specific E2-DNA complex with mo­
bility similar to that of wild-type E2 protein; however, we 
observed considerable retention of the probe in the wells of the 
gel, indicating that mutant E2 proteins may form larger oli­
gomers which are unable to enter the gel. Pronase digestion of 
the lysate revealed protease-resistant cores within the mutant 
E2 proteins (Fig. 4C) as well as the disappearance of the signal 
in wells, supporting the possibility that these mutant proteins 
exist as oligomers or larger aggregates which are still able to 
bind DNA but are unable to enter the gel or nucleus. We 
studied the oligomerization status of wild-type and mutant E2 
proteins in COS-7 lysates by using the sedimentation of this 
protein in 10 to 30% glycerol gradients. Five-milliliter gradi­
ents were dripped into 14 fractions after centrifugation at 
45,000 rpm for 15 h at 4°C with a Beckman SW55 rotor. The 
fractions were analyzed for E2 protein content by a specific 
monoclonal antibody 3F12-based sensitive ELISA and for E2 
protein sequence-specific DNA binding. We used Phospho­
rlmager quantitation of the gel shifts in the region of the 
unit-sized E2-DNA complex and in the region near wells for 
the detection of the larger protein-DNA complex, which has 
difficulties in entering the gel. The results are presented in Fig. 
6. The distribution of the E2 protein from the lysate of COS-7 
cells transfected with the wild-type E2 expression construct is 
shown in Fig. 6A. The E2 protein moves as a single peak in the 
gradient and could be found mostly in fractions 7 and 8. These 
fractions also show the maximal levels of E2 protein DNA 
binding activity. We did not detect any considerable entrap­
ment of the probe in the wells of this gel. For marker proteins, 
alcohol dehydrogenase (150 kDa) peaked in fraction 2 and 
BSA (66 kDa) peaked in fraction 9. We also did not detect any 
wild-type protein precipitated onto the bottom of the centri­
fuge tube (Fig. 6B). From these results, we concluded that the 
wild-type protein exists in COS-7 lysates as a soluble dimeric 
protein. Completely different results were obtained with inac­
tive E2 protein mutants KIHA, K112A, and E176A. Very 
little, if any, E2 protein was detected in the fractions in which 
the dimeric wild-type protein was found. Instead, we detected 
the E2 protein by ELISA in the near-bottom fractions, frac­
tions 1 to 5 (Fig. 6A), and in the precipitated form (Fig. 6B). 
An inspection of the gel shifts indicated that there was very 
little specific E2-DNA complex with the mobility of the wild-
type protein detected in this gel; however, considerable 
amounts of signal could be detected in the regions of this gel 
near wells. An analysis of mutants E74A and D143A/R172C, 
which display weaker DNA binding (Fig. 4A), showed that 
fractions of these mutants exist in the dimeric form, which 
allows some of the specific complex to enter the gel, as well as 
in the oligomeric form, which is capable of binding DNA (Fig. 
6). Some of the oligomers which are stable enough to be 
separated by the glycerol gradient from the dimeric form of E2 
in the case of E74A, were dissociated under the conditions for 
the formation of the E2-DNA complex, and an E2-DNA com­
plex of. the size of the wild-type could be detected in the 
bottom fractions of the gradient (Fig. 6A). From these results, 
we concluded that the inactivity of mutants Kill A, K112A, 
and E176A may be caused by the oligomerization of the pro­
tein, which inactivates the transport of mutant proteins to the 
nucleus. Mutants E74A and D143A/R172C create proteins 
with oligomerization capabilities greater than that of the wild-
type protein; however, this process is reversible and a consid­
erable fraction of the protein still exists in the dimeric and 
active form. 
DISCUSSION 
We constructed a set of BPV1 E2 protein mutants by a 
scheme called clustered charged-to-alanine scan. This ap­
proach allows the identification of functionally important side 
chains involved in interaction with other proteins. Alanine is 
the most abundant amino acid in proteins and was selected as 
the replacement residue because it is found in all types of 
secondary structure and because this substitution does not 
impose new structural effects related to hydrogen bonding, 
unusual hydrophobicity, or steric bulk. Charged-to-alanine 
substitution generally does not interfere with the packing of 
buried residues nor disrupt the structural integrity or expres­
sion of the protein (11). It is highly likely that clustered 
charged residues are exposed on the protein surface.. It is 
reasonable to assume that the functioning of the protein in the 
regulation of different biological activities takes place through 
direct interactions and is mediated through the surfaces of 
components of the system (2). Therefore, clustered charged-
to-alanine scan is a good approach for identifying the struc­
tural determinants of E2 interacting with factors of transcrip­
tion and replication machinery. Our initial analysis of the 
clustered charged residues of the BPV1 E2 protein identified 
about 30 epitopes (determinants) which were located presum­
ably on the surface of the protein and therefore could be 
identified as potential candidates for interactions with basal 
transcription and replication machinery. In the current study, 
we decided to include only the conserved charged residues of 
the BP VI E2 protein. Altogether, 14 E2 mutants with alanine 
substituted for charged residues were constructed by PCR-
mediated mutagenesis. In the process of construction of the 
13th mutation, Asp-143—>Ala, we picked up a double muta­
tion, Asp-143—>Ala and Arg-172—»Cys, which was also in­
cluded in the analysis. Altogether, we tested 15 E2 mutants in 
transient-replication, transcriptional activation, and sequence-
specific DNA binding assays. We found that all E2 mutants, 
except for K111A, K112A, and E176A, were able to activate 
the replication of the BPV1 origin. In addition to these three 
mutants, four E2 mutants, E37A, E74A, D122A, and D143A/ 
R172C, were crippled for the activation of transcription. We 
concluded that only determinants containing residues E-37, 
E-74, D-122, and R-172 are involved in the activation of tran-
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FIG. 6. (A) Sedimentation analysis of wild-type and mutant E2 proteins 
expressed in COS-7 cells. COS-7 eelis were transfected with the respective 
expression vectors for wild-type and mutant E2 proteins, and extracts of trans­
fected cells were loaded onto the top and sedimented through a 10 to 30% 
glycerol gradient. Fourteen fractions were collected, the bottom of the tube was 
washed with 250 |il of buffer, and all fractions were subjected to ELISA analysis 
(optical density at 490 nm [OD490]) (•) and tested for a sequence-specific gel 
shift of the size (in arbitrary units) of the wild tjT>e (O) and for a signal (in 
arbitrary units) near wells (A). DNA binding activities were quantitated with a 
Phosphorlmager, and radioactivity values are expressed in arbitrary units. 
Marker proteins, alcohol dehydrogenase (150 kDa) and BSA (66 kDa), were 
centrifugcd in the parallel gradient and peaked in fractions 2 and 9, respectively, 
b, bottom fraction. (B) Immunoblot analysis of wild-type and mutant E2 proteins 
precipitated upon centrifugation in 10 to 30% glycerol gradients. The precipi­
tated protein at the bottom of the tube was solubilized with 50 |it of SDS sample 
buffer and subjected to Western blot analysis using an E2-specific monoclonal 
antibody. The purified E2 protein expressed in bacteria was used as a control. 
wtE2, wild-type E2. 
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scription and therefore presumably interact with components 
of the transcription machinery. It has been shown that the E2 
protein is able to interact with transcription factor Spl in 
solution and cooperate with Spl in the transcriptional activa­
tion of promoters (17, 26). In addition, E2 has a capacity to 
interact with TBP and with TFIIB (39). Although biochemical 
experiments have demonstrated that major determinants of 
interaction between E2 and TBP and TFIIB lie within the 
carboxy-terminal domain of the E2 protein (39,50), these data 
do not exclude the involvement of certain determinants within 
the transactivation domain in interaction with TBP (39, 50). 
We believe that mutants R37A, E74A, D122A, and D143A/ 
R172C are inefficient in transcription activation because of 
weakened interaction with Spl, TBP, TFIIB, or other general 
transcription factors. Further biochemical studies are in 
progress to identify the interactions of E2 with these factors. 
The amino-terminal domain of the E2 protein has remark­
able structural integrity (7,15,19,23), and very little is known 
about the structural and functional determinants located in 
this part of the E2 molecule. The computer prediction of the 
structure of the N-terminal domain of the BPV1 E2 protein 
was made by the PredictProtein method (41) and is presented 
in Fig. 1A. In addition to our results, two recently published 
studies have analyzed E2 protein functional and structural 
determinants in the N-terminal domain. Human papillomavi­
rus type 16 (HPV16) E2 protein was analyzed by alanine sub­
stitution of conserved residues (42), as in our study, and BPV1 
E2 protein was analyzed by using highly conservative amino 
acid substitutions (7) in the activation of replication and tran­
scription, as well as in interaction with the El protein. A 
comparison of these studies allows us to reach interesting con­
clusions about the structural and functional determinants of 
the E2 protein. The replacement of conserved residues in the 
first alpha-helix (Fig. 1A) with alanine or a conservative amino 
acid does not change the biological or biochemical properties 
of the HPV16 or BPV1 E2 protein. Thus, as in all three studies 
good care in design and characterization of the mutant protein 
was made to avoid gross changes of the structural organization 
of the protein, we may conclude that mutations in positions 
Q-12, E-13, and E-20 of the first alpha-helix have a phenotype 
essentially similar to that of the wild-type protein. At the same 
time, deletion of the first alpha-helix from the BPV1 E2 pro­
tein inactivates E2 completely in all biological assays and re­
veals denatured protein-specific epitopes within the N-termi­
nal part of E2 (23). This allows us to speculate that the first 
alpha-helix is an important structural organizer of the N-ter­
minal part of the E2 protein and determines the integrity of the 
structure of the transactivation domain. This may be achieved 
through electrostatic interaction of the negatively charged first 
alpha helix-surface, consisting of glutamic acid residues. 
In the second alpha-helix of the E2 protein (Fig. 1A), sub­
stitutions for four conserved residues, W-33, R-37, E-39, and 
R-47, have been studied. Conservative changes at two posi­
tions, W-33 and E-39, of BP VI E2 rendered the protein inac­
tive in replication and transcription (7), while alanine substi­
tutions for W-33 and R-47 in HPV16 E2 had no inactivating 
effect and that for E-39 abolished the replicational activation 
ability of E2 (42). In BPV1 E2, the replacement of E-39 and 
R-47 with alanine had little effect on protein activity. The 
replacement of arginine by alanine at position 37 impaired 
HPV16 E2 (42) and BPV1 E2 for transcriptional activation, 
leaving the replication function of the protein intact. The re­
placement of this residue in BPV1 E2 by a conservative amino 
acid, lysine, produced a mutant with an essentially wild-type 
phenotype (7). Although the E2 proteins of different papillo­
maviruses have the same functions, activation of transcription 
and replication, they are not readily interchangeable in repli­
cation assays (9). For example, HPV11 E2 and BPV1 E2 are 
very inefficient in the activation of replication with heterolo­
gous El protein and in interaction with heterologous El pro­
tein (9, 44). This incompatibility of functionally identical pro­
teins in replication assays may be a reflection of differences in 
the structural determinants responsible for the activation of 
replication and may explain the differences in replicational 
activation by E39A mutants of HPV16 and BPV1 E2 proteins. 
In the third alpha-helix (Fig. 1 A), the effects of mutations at 
three positions, R-68,1-73, and E-74, can be compared. Mu­
tation R68A did not induce very large changes in the proper­
ties of E2 proteins (42), while E74A was not studied by others. 
In our study, we found that this protein was transcriptionally 
inactive but moderately functioned in the activation of repli­
cation. Interestingly, mutation I73A in HPV16 E2 induced a 
protein with essentially the same phenotype, while conserva­
tive change I73L produced a BPV1 E2 protein with reduced 
transcriptional activation ability (7). In addition to being im­
paired in transcriptional activation, the same protein with mu­
tation E74A showed another biochemical property. Although 
localized in the nucleus, this mutant protein exhibited an in­
creased ability to form oligomers. These oligomers were still 
able to dissociate into the dimeric form and were able to bipd 
DNA and form an E2-DNA complex of normal size. From 
these three studies, we may conclude that the third alpha-helix 
carries the capacity to interact, presumably through the con­
served determinant between residues 72 and 74 (alanine-iso-
Ieucine-glutamic acid), with the transcription machinery of the 
cell. Hydrophobic and aromatic residues may be critical for 
and participate directly in the interaction of the transcription 
activation domain with components of the basal transcription 
complex (16, 24). We may speculate that the relatively hydro­
phobic isoleucine at position 73 is probably critical for this 
interaction, while a charged residue, E-74, is responsible for 
the presentation of this determinant for interaction. 
We found that substitutions K111A, K112A, and E176A in 
the E2 transactivation domain completely abolished the ability 
of these expressed mutant proteins to form an E2-DNA com­
plex of the usual size; however, considerable retention of the 
probe in wells was detected. The pronase treatment of extracts 
of COS-7 cells containing inactive mutant Kill A, K112A, and 
E176A proteins showed that the DNA binding abilities of 
these mutants were readily present in the proteins; however, 
only large complexes were formed. The formation of oligomers 
and aggregates with these mutants was detected by glycerol 
gradient centrifugation. We also studied the cellular localiza­
tion of mutant E2 proteins and observed that three mutants, 
Kill A, K112A, and E176A, were exclusively localized in the 
cytoplasm. In a study by Skiadopolus and McBride, the BR2 
region (residues 107 to 115) was identified as a potential nu­
clear localization signal for the E2 transactivator protein E2TA 
(46). Two of the mutations, Kl 11A and Kl 12A, fell in the same 
region. Conservative change K111R did not disrupt nuclear 
transport (7, 46); however, this protein was inactive in tran­
scription but retained replicational activity at a very low level. 
This indicates that the lysine residue at position 111 is invariant 
and is important for the active conformation of this protein; 
the replacement of lysine by arginine creates an inactive nu­
clear E2 protein, while a replacement by alanine induces a 
conformation of this protein which is able to oligomerize and 
even to aggregate, as estimated by glycerol gradient centrifu­
gation. In our study, the replacement of lysine by alanine at 
position 112 resulted in a mutant protein with the same phe­
notype as that of Kill A. However, the same mutation in 
HPV16 E2 (42), as well as replacement K112R in BPV1 E2 
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(7), had little effect on the activity of the protein. This discrep­
ancy may be a reflection of the differences in the structures of 
the HPV16 and BPV1 E2 proteins. The BR2 region of the 
BPV1 E2 protein can be responsible for directing E2TA into 
the nucleus (46); however, in our experiments, oligomerization 
and aggregation are probably responsible for the retention of 
mutants Kill A, K112A, and E176A in the cytoplasm. The 
amino-terminal parts of E2 dimeric molecules mediate the 
cooperative binding of E2 on the clustered E2 binding sites in 
DNA (35). This interaction may also take place in solution and 
could serve as a mechanism for the regulation of E2 biological 
activity. Amino terminus-mediated oligomerization could ex­
plain the self-squelching of E2 described by Rank and Lambert 
(39) and by us here. Self-squelching is specific to the E2 trans­
activation domain, as its replacement with the p53 or VP16 
transactivation domain abolished self-squelching, although the 
expression levels of E2 and hybrid proteins were comparable. 
We may conclude that introduced mutations K111A, K112A, 
and E176A remove certain constraints in the interactions of E2 
molecules in solution and induce the formation of inactive 
configurations of E2 oligomers. 
Several studies have presented data consistent with the find­
ing that interaction between BPV1 E2 and El facilitates the 
binding of El to its cognate site (29, 44, 45, 48, 53, 55). This 
cooperative binding has been suggested to play an important 
role in the initiation of BPV1 DNA replication and is very 
specific for El and E2 proteins. We tested a number of trans­
activation domains, p53, VP16, c-jun, and Epstein-Barr virus 
BZLF-1, linked to the E2 DNA binding domain and found all 
of them to be unable to support BPVI origin replication in vivo 
(1). The first 91 residues of E2 participate in interaction with 
the El protein, as shown in biochemical assays and in a two-
hybrid system (3). Eight of our designed mutations fell in this 
region, and curiously none affected the activation of BPV1 
origin replication, though two of them were inactive in tran­
scription. These data indicate that the determinants for inter­
action with the El protein are not encoded by the clustered 
conserved charged residues, but some other sequences within 
this region may be involved in the specific interaction between 
E2 and El. This conclusion is supported by the results of in 
vivo and in vitro replication assays using mixed and matched 
combinations of the El and E2 proteins from BPV1 and 
HPV11 (9, 44). Certain combinations of the El and E2 pro­
teins of BPV1 and HPV11 were inactive for the activation of 
replication, indicating that the interaction between El and E2 
is virus type specific. In contrast, BPV and HPV E2 proteins 
are able to transactivate in different mammalian cell lines and 
in yeasts (36, 49, 54). This indicates that the interactions with 
the transcription machinery are well conserved. Mutations at 
conserved positions lead to the disruption of interactions with 
the transcription machinery but not with El. 
As shown by in vitro replication experiments, transcription 
per se is not required for replication of the BPV1 origin (58). 
Our data also show that the ability of E2 to activate transcrip­
tion is not required at all for the activation of BP VI replication 
in vivo and that the determinants responsible for the activation 
of transcription and replication only partly overlap. 
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The bovine papillomavirus type 1 (BPV-1) E2 protein is the master regulator of papillomavirus replication 
and transcription. We have raised a panel of monoclonal antibodies (MAbs) against the BPV-1 E2 protein and 
used them to probe the structure and function of the protein. Five MAbs reacted with linear epitopes, and four 
M4bs recognized conformation-dependent epitopes which mapped within the C-terminal DNA-binding and 
dimerizaition domain. MAb 1E2 was able to recognize the replication- and transactivaticn-defective but not the 
competent conformation of the transactivation domain of the E2 protein. MAb 5H4 prevented efficiently the 
formation of E2-DNA as well as E2-dependent El-E2-origin complexes and also dissociated preformed com­
plexes in a concentration-dependent manner. Cotransfection of several MAbs with the BPV-1 minimal origin 
plasmid pUCAlu into CH04.15 cells resulted in a dose-dependent inhibition of replication. Inhibition of 
replication by MAb 5H4 and the Fab' fragment of 5H4 correlated with their ability to dissociate the E2 protein 
from the DNA. MAb 3F12 and MAbs 1H10 and 1E4, directed against the hinge region, were also capable of 
inhibiting BPV-1 origin replication in CH04.15 cells. However, the Fab' fragments of 1H10 and 3F12 had no 
effect in the transient replication assay. These data suggest that MAbs directed against the hinge region 
sterically hinder the inter- or intramolecular interactions required for the replication activity of the E2 protein. 
Bovine papillomavirus type 1 (BPV-1) has been studied ex­
tensively as a model for papillomavirus replication and tran­
scription. The viral E2 protein is the master regulator of the 
viral life cycle—this protein modulates the transcription of 
viral genes (41) and is responsible for the initiation of DNA 
replication (43, 44, 48) and for the stable maintenance of the 
viral genome (31), which is achieved presumably through fa­
cilitation of the association of the viral genome with chromatin 
(19a, 23, 40). E2 is a sequence-specific DNA-binding protein, 
and it interacts with the components of the cellular transcrip­
tion (33, 49) and replication (24) machinery. The viral E2 and 
El proteins interact with each other (2, 4, 30, 35) during the 
initiation of replication, resulting in cooperative binding of El 
and E2 on the BPV-1 replication origin (25-27, 35-39). 
The BPV-1 E2 protein, like other transcription factors, is 
composed of relatively well-defined function-specific modules. 
Structural and mutational analyses have revealed three distinct 
domains. The amino-terminal part (residues 1 to 210) is an 
activation domain for transcription (12, 28) and replication 
(43). It is followed by the unstructured hinge region and the 
carboxy-terminal DNA-binding and dimerization domain (res­
idues 310 to 410) (29). Deletion analysis of the E2 protein has 
shown that the transactivation domain and the DNA-binding 
and dimerization domains are necessary for both replication 
and transcription, while large deletions in the hinge region 
affect replication preferentially and transcription less (46). The 
structure of the carboxy-terminal DNA-binding and dimeriza­
tion domain has been solved by X-ray analysis and has revealed 
a dimeric DNA-binding and dimerization motif (15, 16). Most 
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of the information about structural and functional determi­
nants in the amino-terminal activation domain of the E2 pro­
tein has been obtained by mutational analysis (7, 12, 14, 46). 
These data confirm that the E2 amino-terminal domain, like 
the C-terminal domain, has a highly organized structure and 
that even a single point mutation can inactivate the function of 
the E2 protein in the activation of transcription, replication, or 
both (1, 5, 9, 13, 34). 
Antibodies are efficient and highly specific tools for identi­
fying the structural determinants of macromolecules and/or for 
studying the role of a protein in functional assays (18, 19, 21, 
42, 45). Antibodies have been used for the characterization of 
the human papillomavirus (HPV) E2 protein. For example, 
polyclonal antibodies against overlapping synthetic peptides 
that cover the HPV -type 16 (HPV-16) E2 protein have been 
used to test the structure of this protein (10), and the interac­
tion of the HPV-16 E2 protein with the El protein could be 
blocked by a monoclonal antibody (MAb) that bound E2 in the 
region of amino acids 18 to 41 (17). 
In this study, we describe the production of a set of MAbs 
against the BPV-1 E2 protein and characterize their ability to 
interfere with the functions of the E2 protein in vivo and in 
vitro in biochemical and functional assays. 
MATERIALS AND METHODS 
Production of the BPV-1 EZ protein. E2 protein was expressed in the pETl lc-
based system in Escherichia coli and was purified to homogeneity by conventional 
methods (37) with modifications. First, we precipitated nucleic acids from clar­
ified cell lysates by the slow addition of polycthylenimine (Polymin P; Sigma) to 
a final concentration of 0.6%. Precipitation was carried out on ice for 30 min, and 
the pellet was collected by centrifugation. Proteins were recovered from the 
supernatant by precipitation with 35% ammonium sulfate and purified to homo­
geneity by conventional chromatography. 
Production of MAbs. Female BALB/C mice were injected with 50 M-g of 
purified BPV-1 E2 protein five times at 3- to 4-week intervals. The injections 
were intraperitoneal, with E2 suspended initially in Freund's complete adjuvant 
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and subsequently in phosphate-buffered saline (PBS). Following the final injec­
tion, mice were allowed to rest for 5 weeks and then were injected with 100 ng 
of antigen. One week later, final boosts with 100,200, and 200 (ig of protein in 
PBS at 4, 3, and 2 days before fusion, respectively, were performed. Sp2/0 
myeloma cells and cells from one third of the spleen were washed three times 
with sterile PBS. The final pellet was mixed by tapping the tube, and 1 ml of 50% 
polyethylene glycol (PEG) 4000 (Merck) was added over 1 min with gentle 
shaking. The cells were centrifuged at 100 X g for 5 min, the PEG solution was 
removed, and the resuspended cells were plated on five 96-weII microtiter plates 
containing hypoxanthine-aminopterin-thymidine medium. Supernatant: were 
tested 10 days after fusion as described below by a direct enzyme-linked immu­
nosorbent assay (ELISA). 
Screening at hybridomas. Wells of ELISA plates (Maxisorp; Nunc, Roskilde, 
Denmark) were coated with 100 pi of E2 (2 Mg/ml in PBS) overnight at 4°G 
After the coating step, the plates were washed three times with PBS containing 
0.05% Tween 20 (PBS/T) and blocked with PBS/T containing 0.05% casein for 
30 min. Then, 80 >d of PBS/T and 20 |il of hybridoma supernatant: were added 
to the wells, and the plates were incubated for 60 min on a shaker at room 
temperature. The plates were washed with PBS/T, followed by the addition of 
300 |il of peroxidase-conjugated goat anti-mouse immunoglobulin G (IgG) (La-
bAS Ltd., Tartu, Estonia) diluted 1:2^00 in PBS/T supplemented with 2% PEG 
6000 (Merck). The plates were incubated for 15 min and then washed with 
PBS/T. Then, 100 jil of TMB substrate solution ß^'W-tetramethylbenzidine-
HjOj in 0.1 M acetate-citrate buffer [pH 4.5]) was added. 
The antibody subclasses were determined by an ELISA as described above 
with peroxidase-labelled goat anti-mouse isotype antibodies (LabAS). 
Purification of MAbs. The MAbs were purified from ascitic fluid by ammo­
nium sulfate precipitation and ion-exchange chromatography on Blue DEAE-
Toyopearl 650S with a Pharmacia standard fast protein liquid chromatography 
system (20). The IgG concentration was estimated at 280 nm by use of an 
extinction coefficient of 14. The purified MAbs were stored in PBS containing 
50% glycerol at -20°C. 
Preparation of Fab' fragments. Fab' fragments were prepared from the MAbs 
as described by Porter (32) with modifications. The MAbs were dialyzed against 
0.1 M sodium acetate buffer (pH 5.5) containing 1 mM EDTA and 25 mM 
2-mercaptoethanol. The antibodies were digested with papain at an enzyme/ 
antibody ratio of 1:10 (wt/wt) for 24 h at 37*C. The reaction was stopped by the 
addition of iodoacetamide to a final concentration of 30 mM. The digested 
antibodies were dialyzed against 20 mM Tris-HCI buffer (pH 7.2), and Fab' 
fragments were purified on a Mono Q column. 
Peptide synthesis. Peptides were assembled in a stepwise manner on a solid 
support with a model 431A peptide synthesizer (Applied Biosystems) by the 
standard NMP/HOBt solvent activation strategy on a 0.1-mmol scale (22). 
ELISA with peptides. The surfaces of the microtiter wells were activated with 
0.25% glutaraldehyde in PBS for 30 min at 60°C. The plates were washed three 
times with PBS, and a peptide solution at a concentration of 20 |ig/ml in PBS was 
added to the wells. The plates were incubated overnight at room temperature, 
washed with PBS/T, and blocked with 1% nonfat dry milk in PBS/T for 2 h. The 
plates were washed with PBS/T, and antibodies diluted in PBS/T were added to 
the wells, incubated, and processed as described above. 
Plasmids. The pET-E2 vector used for the expression of E2 in E. coli was 
generated by PCR amplification with specific primers and was cloned between 
the NdcI and BamHl sites of plasmid pETllc. The E2 expression constructs 
pCGE2, pCGE2C, pCGE8/E2, and pCGE2(D92-161) have been described pre­
viously (43,44). Plasmid VP16:E2 (24) contains 80 C-terminal amino acids from 
VP16 fused to the C terminus of E2 (starting from amino acid 250) in the context 
of pCG. The E2 N-terminal deletion mutants E2(Dl-23), E2(Dl-85), E2(D1-
112), and E2(D1-183) were generated by PCR with appropriate oligonucleotide 
primers containing an initiation methionine codon in the optimal Kozak context 
and were cloned into the pCGE2 expression vector at the Xbal-BomHl sites. For 
the E2 C-terminal deletion mutants E2(D219-410), E2(D284-410), and 
E2(D310-410), PCR primer pairs were designed with terminal recognition se­
quences for Kjml-Bctl and were cloned into the corresponding sites in pCGE2. 
The replication reporter plasmid pUCAlu has been described previously (43). 
pHookAlu was made by cloning the Alu fragment from pUCAlu at the 
HindUI-BamHI sites of pHook-2 (Invitrogen) and deleting the cytomegalovirus 
promoter with restriction enzymes Hmdlll and fiuHI. 
Cells and transactions. E2 expression constructs (100 ng) were electroporated 
at 180 V into COS-7 cells (2 X 10s to 6 X 10®) in 250 (il of Dulbecco modified 
Eagle medium supplemented, with 10% fetal calf serum (FCS) and 50 c-g of 
denatured salmon sperm DNA at room temperature (43). For replication assays, 
CH04.15 cells were trypsinized, centrifuged, and resuspended in F12 medium 
containing 10% FCS at a density of 107 cells/ml. The cell suspension (250 |il) was 
mixed with 100 ng of pUCAlu DNA, 50 |ig of salmon sperm DNA and various 
concentrations of MAbs or Fab' fragments in a disposable electroporation cu­
vette and subjected to an electric discharge of 230 V from an Invitrogen Gene 
Pulser. After the discharge, the cell suspension was left at room temperature for 
15 min, and then the cells were washed and plated in F12 medium supplemented 
with 10% FCS. The extraction of episomal DNA from cells and its analysis by 
Southern blotting were performed as described previously (43). For Western blot 
analysis, 500 ng of pHookAlu was cotransfected with MAbs (80 |ig/ml), and 
transiently transfected cells were separated from the total population of 
CH04.15 cells with magnetic beads (Invitrogen) according to the manufacturer's 
recommendations. 
Immunoblotting of E2. COS-7 cells transfected with E2 proteins in 60-mm 
diameter dishes were lysed 36 h after electroporation in 200 (il of Laemmli 
sample buffer. Transfected CH04.15 cells were separated from the magnetic 
beads by boiling in 100 |d of Laemmli sample buffer. Proteins were separated by 
sodium dodecyl sulfate-10% Polyacrylamide gel electrophoresis (PAGE). After 
transfer, the nitrocellulose membranes were incubated with mouse E2-specific 
MAbs and a secondary horseradish peroxidase-conjugated antibody by use of an 
ECL detection kit (Amersham) according to the manufacturer's recommenda­
tions. To analyze the E2 protein level in CH04.15 cells transfected with MAbs, 
rabbit anti-E2 polyclonal antibody was used. 
Mobility shift assays. For preparation of COS-7 cell extracts, transfected cells 
were removed from semiconfluent growth on 100-mm-diameter plates with a 
rubber policeman, washed, and lysed in 100 |il of lysis buffer (20 mM Tris-HCI 
[pH 8.0], 100 mM NaCi, 30 mM KCl, 0.1 mM EDTA 0.35% Nonidet P-40,10 
mM dithiothreitol, protease inhibitors) on ice for 30 min. Cell debris was re­
moved by centrifugation, glycerol was added to a final concentration of 20%, and 
the extracts were divided into aliquots and stored at -70°C. For gel shift assays, 
2 |il of cell extract was incubated in 10 |il of binding buffer (10 mM Tris-HCI (pH 
7.5], 100 mM KCl, 2 mM dithiothreitol, 0.5 mM phenylmethylsulfonyl fluoride, 
15% glycerol, 5 mg of bovine serum albumin per ml, 1 ng of leupeptin per ml, 1 
|ig of aprotinin per ml) at room temperature for 15 min in the presence of 1 |tg 
of sonicated salmon sperm DNA and 0.2 ng of 32P-labelled oligonucleotide 
containing the E2 binding site. For bacterially expressed E2,2 ng of protein was 
used per reaction. Double-stranded high-affinity binding site 9 of BPV-1 (5'-A 
CAAAGTACCGTTGCCGGTCGAA-3'1 was used as a probe. Protein-DNA 
complexes were resolved by 6% PAGE (acrylamidc-WJV-methylene-bisacrylam-
ide, 80:1) with 0.25X Tris-borate-EDTA. Gels were dried and exposed to X-ray 
film. MAbs (1 to 10 ng/|il) were added either before or after DNA binding and 
were incubated for an additional 20 min. For protease digestion experiments, 
bacterially expressed E2 protein was incubated with 2 ng of pronase for 5 min. 
The El-E2-origin complex formation assay was performed as described by Sed-
man and Stenlund (35). The effect of antibodies on El-E2-origin complex for­
mation was tested either before or after the assembly of the complex. 
RESULTS 
Generation of E2-specific MAbs. The soluble E2 protein was 
purified to apparent homogeneity from lysates of isopropyl-ß-
D-thiogalactopyranoside (IPTG)-induced E. coli overexpress-
ing BPV-1 E2 from the pETllc expression vector by conven­
tional chromatography (37). BALB/c mice were immunized 
with the purified functionally active E2 protein as described in 
Materials and Methods. We obtained nearly 200 hybridoma 
cell lines, 17 of which were positive for the E2 protein in both 
ELISAs and immunoblot assays, while 5 hybridomas were pos­
itive in ELISAs only. Nine MAbs that were deemed most 
useful were purified from the ascitic fluids of the respective 
hybridoma cell lines and studied in various assays as described 
below (Table 1). All studied antibodies belonged to the IgGl 
subtype, with the exception of 3C1, which belonged to the 
IgG2a subtype. All of these MAbs had high affinities for and 
fast kinetics of binding to their respective epitopes, as found by 
the concentration dependence of antibody binding in ELISAs 
(data not.shown). 
Epitope mapping. To define the continuous epitopes recog­
nized by the antibodies, the reactivity of each MAb to full-
length and truncated E2 proteins expressed in COS-7 cells was 
determined by Western blot analysis. The linear epitopes for 
the initially isolated 17 MAbs were mapped in the region 
between amino acids 184 and 309; for 12, the epitopes were 
found within the region between residues 184 and 218 (data 
not shown). We concluded from these results that the se­
quence of the 34 amino acids within the region from residues 
184 to 218 is the major immunodominant determinant of the 
BPV-1 E2 protein. TTie results of immunoblot analysis for five 
selected purified antibodies with the linear epitopes are shown 
in Fig. 1A. To map the epitopes for the 1E2, 3F12, and 1H10 
antibodies more precisely, we synthesized four overlapping 
peptides covering the region between amino acids 162 and 210. 
The sequences of the synthesized peptides and the ability of 
the MAbs to bind to these peptides in an ELISA are shown in 
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TABLE 1. MAbs recognizing the BPV-1 E2 protein" 
Transactivation 
1E4 3C1 3ES. 3H5,5H4 
Antibody 
Location 
of 
epitope 
(residues) 
Type 
of epitope 
Binding to 
E2-DNA 
complex 
Inhibition Binding 
of E2 to E1-E2-
binding origin 
to oligo complex 
1E2 184-190 Linear _ - -
3F12 199-206 Linear + - + 
1H10 208-218 Linear + - + 
1E4 250-280 Linear + - + 
3C1 280-309 Linear + - + 
3E8 310-410 Conformational + - -f 
3H5 310-410 Conformational + - + 
5F10 162-410 Conformational + - + 
5H4 310-410 Conformational 
-
-
' +, positive result; —, negative result. 
Fig. IB. Peptides P2 (residues 171 to 192) and P3 (residues 184 
to 201) were recognized by 1E2, while peptide P4 was recog­
nized by 3F12. To narrow down the sizes of the epitopes, two 
additional peptides, P5 (residues 179 to 190) and P6 (residues 
197 to 208), were synthesized and confirmed by an ELISA to 
contain the recognition sequences for the 1E2 and 3F12 anti­
bodies, respectively. 1H10 did not recognize any of the synthe­
sized peptides and was therefore mapped by the Western blot 
analysis to the region between amino acids 208 and 218. 
To test the ability of the antibodies to recognize their re­
spective linear epitopes on the E2 protein in the E2-DNA 
complex, a mobility shift assay was used. All MAbs against the 
linear epitopes, with the exception of 1E2, were able to induce 
a supershift (Fig. 2A), indicating that their epitopes are ex­
posed on the surface of the DNA-bound E2 molecule. 
Accessibility of the MAb 1E2 epitope in the E2 protein. The 
epitope for MAb 3F12 (residues 199 to 206) is efficiently ex­
posed in the DNA-bound E2 protein, while the epitope for 
MAb 1E2, located 8 residues upstream, is poorly recognized by 
the respective antibody in the full-length E2 protein in complex 
with DNA (Fig. 2A, compare lanes 2 and 3 with lanes 4 and 5). 
However, the epitope for MAb 1E2 was readily exposed in 
truncated E2 proteins bound to DNA—E2(Dl-23). E2(D1-
85), E2(D1-112), E2(D1-183), and E2C (Fig. 2C)—as well as 
in the internal deletion mutant E2(D92-161) (data not shown). 
All of these deletion mutants were inactive for the activation of 
transcription and replication (21a). Therefore, the epitope for 
MAb 1E2 could be identified as a transactivation domain de-
naturation-specific epitope of the E2 protein; the exposure of 
the 1E2 epitope indicates that the E2 protein transactivation 
domain has an inactive conformation for transcription and 
replication. 
Antibodies against the C-terminal domain of the E2 protein. 
MAbs 3E8, 3H5, 5F10, and 5H4 did not react with the E2 
protein on immunoblots, indicating that the epitopes of these 
MAbs are sensitive to denaturation. To define further the 
A., Monoclonal Antibody 
IE2 3F12 1H10 1E4 3C1 conf. 
wtE2 + + + + + -
E2(Dl-23) + + + + + — 
E2(Dl-85) + + + + + -
E2(D1-112) + + + + + -
E2(D1-183) + + + + + -
E2£D91-161) + + + + + -
E2(D219-410) + + + - - -
E2(D284-410) + + + + - -
E2{D310-410) 4 -  +  +  +  + • —  
E2C + + + + + -
E8/E2 : - - + + + -
VP16/E2 - - - + + -
B. 
E2C E8/E2 
160 1 170 180 190 200 5 ^ Monoclonal Antibody 
GLYYCTMAGAOPJYYSRFGDEAARFSTTGHYSVRDQDRVYAGVSSTSSDFRDRPD 1E2 3F12 1H10 
PI MAGAGRIYYSRFGDEAARFSTT -
P2 SRFGDEAARFSTTGHYSVRDQD + 
P3 GHYS VRDQDRVY AGVSST + 
P4 DRVYAGVSSTSSDFRDRPD + 
P5 RFSTTGHYSVRD + 
GVSSTSSDFRDR + P6 
FIG. 1. Epitope mapping of E2-speciflc MAbs. (A) Schematic representation of the truncated E2 proteins used and the results of the immunoblot analysis of the 
f~£r°,ln.5\„g,ra™a' r,fES'.wt' *'!?, Vpe: <*»'•. MAbs with discontinuous epitopes. (B) Reactivity of MAbs to synthetic peptides (PI to P6) covering the region from 
amino acds 162 to 210 of E2 in an ELISA +, positive result; -, negative result. r r v s e* 
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FIG. 2. Characterization of E2-specific MAbs. (A) Reactivity of E2-spccific MAbs with the native E2 protein. The mobility shift assay was carried out with 2 ng of 
bacterially expressed and purified E2 protein and 0.2 ng of radiolabeled E2 binding site for 15 min at room temperature. (B) Lanes 1 to 10 show reactivity of MAbs 
with discontinuous epitopes with truncated E2 proteins expressed in COS-7 cells. Band shift assays were performed with 2 jil of cell extract. Lanes 11 to 16 show 
reactivity of MAbs to the E2 DNA-binding domain (DBD). Bacterially expressed E2 protein was treated with 2 jxg of pronase for 10 min at room temperature, and 
then reactivity was determined. (C) Reactivity of MAb 1E2 with truncated E2 proteins expressed in COS-7 cells. MAbs '.vere added after E2 was mixed with its DNA 
target, neg., ceils transfected with carrier only; wt, wild type. Protein-DNA complexes were resolved by 6% PAGE with 0.25X Tris-borate-EDTA. 
1E2 3F12 1H1Q 1E4 3C1 Mat» 
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epitopes for these MAbs, the reactivity of each MAb to the 
full-length or truncated E2 protein expressed in COS-7 cells 
was determined by a gel shift assay. All four studied antibodies 
were able t© react with both the full-length E2 protein (data 
not shown) and E2C expressed in COS-7 cells (Fig. 2B, lanes 
1 to 5). MAbs 3E8, 3H5, and 5F10 were able to induce a 
supershift, and MAb 5H4 prevented the formation of the E2-
DNA or E2C-DNA complex (Fig. 2B, lane 5; see also Fig. 5A, 
lanes 2 to 5). MAb 5H4 not only prevented the formation of 
the E2-DNA complex but also dissociated the preformed E2-
DNA complex, and this effect was dependent on the concen­
tration of the antibody. The dissociation of the preformed 
complex required concentrations of MAb 5H4 higher than 
those required to block complex formation. The chimeric pro­
tein VP16-E2, which contains amino acids 250 to 410 of the E2 
protein, was recognized by MAbs 3E8, 3H5, and 5H4 but 
poorly, if at all, by MAb 5F10 (Fig. 2B, lanes 6 to 10). 
The carboxy-terminal DNA-binding and dimerization do­
main of the E2 protein forms a protease-resistant core (8). 
When the E2 protein was incubated with pronase prior to the 
addition of antibodies, the DNA-binding domain of the E2 
protein was still able to interact with MAbs 3E8,3H5, and 5H4 
and weakly with MAb 5F10 (Fig. 2B, lanes 11 to 16), resulting 
in a supershift or dissociation of the E2-DNA complex. These 
data allowed us to map the epitopes for the conformational 
MAbs 3E8, 3H5, 5F10, and 5H4 within the carboxy-terminal 
~100 residues of the E2 protein. Immunoprecipitation studies 
with truncated E2 proteins mapped the epitopes for these 
MAbs within amino acids 310 to 410 (data not shown). The 
epitope mapping for MAb 5F10 was less definitive because the 
accessibility of the epitope for this MAb was dependent on the 
context of the protein. Although this MAb recognized an 
epitope in the E2-DNA and E2C-DNA complexes, the same 
epitope in VP16-E2 and the E2 DNA-binding and dimeriza­
tion domain (Fig. 2B, compare lanes 4, 9, and 15) was poorly 
recognized. 
Effect of MAbs on El-E2-origin complex formation. The 
BPV-1 minimal origin of replication comprises the El binding 
site, the A/T-rich region, and the E2 binding site (44). The El 
and E2 proteins bind cooperatively to the origin and form an 
El-E2-origin complex (27, 35, 39). It has been shown that the 
ability of the E2 protein to form a complex with the El protein 
on DNA correlates with the efficiency of initiation of replica- ' 
tion in vivo (11, 36). We studied the effect of the antibodies on 
E2-dependent El-E2-origin complex formation. Antibodies 
3F12,1H10,1E4,3C1,3E8,3H5, and 5F10 all recognized their 
respective E2 epitopes in the El-E2-origin complex and super-
shifted this complex (Fig. 3A, lanes 3 to 9). Interestingly, MAbs 
which recognize the C-terminal part of the E2 molecule re­
sulted in an El-E2-origin MAb complex which migrated much 
more slowly than complexes in which the MAbs bound to 
epitopes closer to the center of the E2 molecule. The epitope 
for MAb 1E2 is masked in the DNA-bound E2 protein and 
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FIG. 3. Effect of E2-specific MAbs on the formation of the Ei-EZ-origin 
(ori) complex. (A) A gel mobility shift assay was performed v/ith 2 ng of El 
protein and 5 ng of E2 protein for 20 min. MAbs were added to a final concen­
tration of 10 ng/|j.l and incubated for an additional 20 min. (B) A gel mobility 
shift assay was used to analyze the complex formed in the presence of El only. 
The resulting complexes were treated with 0.4% glutaraldehyde and separated 
on agarose gels. 
4674 KURG ET AL, J. VIROL. 
remains nonaccessibie to this antibody in the E1-E2-DNA 
complex (Fig. 3A, lane 2). MAb 5H4, which specifically disso­
ciated E2 from DNA, prevented the formation of the E1-E2-
origin complex (Fig. 3A, lane 10). None of the antibodies had 
any effect on the mobility of the El-origin complex formed at 
a high El protein concentration (Fig. 3B). These results 
showed that the epitopes for the most studied MAbs, with the 
exception of 1E2, are exposed in the El-E2-origin complex and 
that MAb 5H4 is the only antibody which interferes with E2-
dependent El-E2-origin complex formation. 
Effect of anti-E2 MAbs on BPV-1 origin replication in cells. 
The observation that antibodies recognized their respective 
epitopes in the DNA-bound E2 protein raised the possibility 
that some of these antibodies could interfere with some func­
tions of the E2 protein in the initiation of DNA replication in 
vivo. Therefore, the purified antibodies were tested in a tran­
sient replication assay in vivo for their ability to block E2 
protein functions in BPV-1 origin replication. Transfer of the 
MAbs into mammalian cells was carried out by electroporation 
(6). The transfection conditions were optimized to a level 
which allowed the uptake of both DNA and protein into 
CH04.15 cells, which constitutively express viral El and E2 
proteins (31) (see Materials and Methods). The presence of 
the relatively high concentrations of antibodies in the transfec­
tion mixture had no effect on CH04.15 cell growth. We esti­
mated that 1 to 2% of the input antibody was taken up by the 
cells under these conditions, as determined by Western blot 
analysis. Analysis of the cells immediately and 24 and 48 h after 
transfection showed structurally intact immunoglobulin heavy 
chains within the cells, indicating that no active degradation of 
the transfected antibodies took place in the cells (data not 
shown). 
Different amounts of E2-specific MAbs were cotransfected 
with 100 ng of origin-containing plasmid pUCAlu by electro­
poration into CH04.15 cells. Episomal DNA was extracted by 
alkaline lysis at 2 or 3 days after transfection, purified, digested 
with Dpnl and linearizing enzyme HindUl, and analyzed by 
Southern blotting as described earlier (43). The effect of the 
E2-specific antibodies on the replication of the BPV-1 origin 
was dependent on the antibody concentration used (Fig. 4A). 
At a low concentration (20 |xg/ml), MAb 1H10 strongly inhib­
ited and MAbs 3F12 and 1E4 moderately inhibited the repli­
cation of origin-containing plasmid pUCAlu in CH04.15 cells. 
The inhibition of replication by MAbs 3F12, 1H10, and 1E4 
became almost complete when the antibody concentration in 
the cell suspension was increased to 80 p-g/ml (Fig. 4A and B, 
lanes 3 to 5). MAb 5H4, which efficiently inhibited the forma­
tion of both E2-DNA and El-E2-origin complexes in vitro, 
exhibited only a weak inhibitory effect in the transient replica­
tion assay at a low concentration. However, at a higher con­
centration (80 jjig/ml), strong inhibition of replication was 
achieved with MAb 5H4 (Fig. 4A and B, lane 10). MAbs 1E2, 
3C1,3E8,3H5, and 5F10 exhibited only weak inhibition, and a 
nonrelated anti-ß-galactosidase MAb had no effect on origin-
containing plasmid pUCAlu replication at all concentrations 
tested. The differences in the abilities of the MAbs to inhibit 
replication were not caused by differential uptake of MAbs by 
cells, since equivalent concentrations of intracellular MAbs 
were used in the cell suspension during electroporation and 
comparable amounts of the antibodies were detected in the 
cells by Western blotting (data not shown). The affinities of all 
of these antibodies were similar, as indicated by the concen­
tration-dependent binding of the antibodies in the ELISA 
(data not shown). 
We next studied the effect of the E2-specific MAbs on the 
steady-state level of the E2 protein and on the localization of 
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FIG. 4. Effect of E2-specific MAbs on papillomavirus replication. (A) 
CH04.1S cells constitutively expressing BPV-1 El and E2 proteins were elec­
troporated with 100 ng of reporter plasmid pUCAlu and various concentrations 
of MAbs. Cells were harvested 72 h after electroporarion. Episomal DNA was 
digested with Dpnl and linearizing'enzyme flindlll and analyzed by Southern 
blotting. The replication signals of three independent experiments were quanti­
fied with a Phosphorlmager, and signals from cells transfected with the origin-
containing plasmid only were used as a control to normalize the results. Symbols: 
®, MAb 3Fl2; O, MAb 1E4; A, MAb 1H10; H, MAb 5H4; •, nonspecific 
anti-ß-galactosidase (ß-gal) MAb. (B) Southern blot analysis of transient repli­
cation of the BPV-1 origin-containing plasmid pUCAlu in the CH04.15 cell line 
in the presence of MAbs at a concentration of 80 n^tal. Episomal DNA was 
extracted from cells 72 h after transfection. Filters were probed with radiola-
belled plasmid pUCAlu. (C) Western blot analysis of E2 protein levels in trans­
fected CH04.15 cells with rabbit anti-E2 polyclonal antibody. 
this protein in transfected cells. To select and isolate tran­
siently transfected cells from the total population of CH04.15 
cells, a Capture-Tec Hook-2 kit (Invitrogen) was used. Briefly, 
MAbs were cotransfected with 500 ng of the origin-containing 
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plasmid pHookAlu, which expresses a fusion protein com­
prised of the PDGFR transmembrane domain fused to the 
variable region of the antibody capable of recognizing phOx 
(4-etoxymethylene-2-phenyl-2-oxazolin-5-one), into CH04.15 
cells. At 24 h after electroporation, transfected cells were se­
lected with magnetic beads carrying immobilized phOx and 
analyzed for the level of the E2 protein by Western blotting as 
well as for the localization of the E2 protein by direct immu­
nofluorescence analysis with rabbit anti-E2 polyclonal anti­
body. We did not find any effect of the cotransfected E2-
specific MAbs on the localization (data not shown) or steady-
state level of the E2 protein in CH04.15 cells (Fig. 4C). 
Effect of Fab' fragments on DNA replication. Our results 
showed that MAbs 1H10, 1E4, 3F12, and 5H4 suppressed 
BPV-I origin replication in a dose-dependent fashion (Fig. 
4A). At the same time, MAbs 1H1G, 3F12, and 1E4 did not 
influence the formation of the El-E2-origin complex and su-
pershifted this complex efficiently (Fig. 3, lanes 3 to 5). These 
data suggest thai MAb 3F12 (epitope at residues 199 to 206) 
and MAbs 1H10 and 1E4, directed against the hinge region of 
the E2 protein, would not interfere directly with El and E2 
interactions with DNA; however, these antibodies can steri-
cally interfere with the inter- or intramolecular interactions 
required for the replication activity of the E2 protein. In order 
to study the possibility that antibodies would have an effect on 
replication due to steric hindrance of the formation of the 
replication initiation complexes, the Fab' fragments of MAbs 
3F12, 1HI0, and 5H4 were prepared by a modified procedure 
(see Materials and Methods). An ELISA with E2-coated mi­
crotiter plates showed that all of the Fab' fragments were 
active in binding to the E2 protein. The affinities of the Fab' 
fragments of 1H10 and 5H4 were similar, while the Fab' frag­
ment of 3F12 had a lower affinity, as determined by titration on 
the ELISA plates (data not shown). 
The produced Fab' fragments were tested in biochemical 
assays as well. The ability of the MAb 5H4 Fab' fragment to 
inhibit the formation of the E2-DNA complex is shown in Fig. 
5A. Concentrations of MAb 5H4 and its Fab' fragment of 1 
ng/|j.l and at least 10 ng/jxl, respectively, were required to 
prevent the formation of the E2-DNA complex (Fig. 5A). The 
MAb 5H4 Fab' fragment was also capable of dissociating the 
preformed E2-DNA complex (data not shown). 
We transfected 100 ng of origin-containing plasmid pUCAlu 
in the presence of increasing concentrations of Fab' fragments 
into CH04.15 cells by electroporation. A representative rep­
lication assay is shown in Fig. 5B and C. The Fab' fragment of 
MAb 1H10 had no significant inhibitory effect on DNA repli­
cation at any concentration tested (Fig. 5B and 5C, lanes 5 and 
6). The Fab', fragment of MAb 3F12 activated rather than 
inhibited replication (Fig. 5B and C, lanes 3 and 4), and the 
12 3 4 5 6 7 8 
FIG. 5. Effect of E2-specific Fab' fragments on DNA replication. (A) Ability 
of MAb SH4 and its Fab' fragment to inhibit the formation of the E2-DNA 
complex at various antibody concentrations. The mobility shift assay was carried 
out with 2 ng of bacterially expressed and purified E2 protein and 0.2 ng of 
radiolabeled E2 binding site for IS min at room temperature. MAb SH4 or its 
Fab' fragment was added after E2 was mixed with its DNA target, and incubation 
was carried out for an additional 20 min. (B) Inhibition of DNA replication by 
E2-spccific Fab' fragments at various concentrations. Reporter plasmid pUCAlu 
(100 ng) was cotransfected together with the Fab' fragment of 3F12(*), the Fab' 
fragment of 1H10 (•), or the Fab' fragment of 5H4 (A) into cell line CH04.15. 
At 72 h after electroporation, cells were harvested, and episomal DNA was 
digested with Dpnl and linearizing enzyme Hindlll and analyzed by Southern 
blotting. The replication signals of three independent experiments were quanti­
fied with a Phosphorlmager, and signals from cells transfected with the origin-
containing plasmid only were used as a control to normalize the results. (C) 
Southern blot analysis of transient replication of the BPV-1 origin-containing 
plasmid pUCAlu in the CH04.15 cell line in the presence of Fab' fragments at 
a concentration of 0.3 mg/ml. Episomal DNA was extracted from cells either 48 
or 72 h (-a) after transfection. Filters were probed with radiolabeled plasmid 
pUCAlu. 
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Fab' fragment of MAb 5H4 inhibited BPV-1 origin replication 
(Fig. 5B and 5C, lanes 7 and 8) in a dose-dependent fashion. 
DISCUSSION 
The crystal structure of the DNA-binding domain of the E2 
protein with and vwithout DNA has been solved (15,16). Until 
the crystal structure of the full-length E2 protein is deter­
mined, we will have to rely on other methods to examine the 
structural organization of the whole protein and the molecular 
interactions that must occur to accomplish the replication 
and/or transcription activity of the protein. Even if the crystal 
structure were known, information about possible interactions 
should be gathered by other methods. In this study, we have 
produced and characterized a panel of MAbs as probes and 
tools for studying the structure and function of the BPV-1 E2 
protein. 
A total of 22 MAbs that were reactive to the E2 protein in 
an enzyme immunoassay were isolated. Seventeen of these 
MAbs were directed against linear epitopes that were mapped 
within the region between amino acids 180 and 309 of E2. In 
fact, the last part of the amino-terminal transactivation domain 
and the first 10 amino acids of the hinge region, residues 180 to 
218, appear to constitute a highly immunogenic "hot spot," 
since epitopes for 12 of these 17 MAbs were found to be 
localized within this region. The reason for the highly immu­
nogenic properties of the region between residues 180 and 218 
is unknown. Epitopes for 5 of the 22 MAbs were mapped 
within the C-terminal DNA-binding and dimerization domain. 
Interestingly, all of these antibodies recognized the composite 
epitopes and did not react with the denatured E2 protein. 
None of the epitopes for the MAbs tested were mapped to the 
first 180 residues of the E2 protein. 
When only a purified transactivation domain, residues 1 to 
218, of E2 was used for immunization, four MAbs against the 
region between amino acids 1 and 180 of E2 were obtained; 
however, none of them was able to recognize the E2-DNA 
complex in a mobility shift assay (21a). In contrast, Hibma and 
coworkers (17) raised antibodies against the N-terminal part of 
the HPV-16 E2 protein, indicating that the HPV-16 and 
BPV-1 E2 proteins are considerably different in terms of struc­
ture and epitope presentation. The most antigenic regions are 
usually the less ordered regions of the protein without packed 
internal side chains. From this point of view, the differential 
antigenicity may be a reflection of the differences in the struc­
tures of the HPV-16 and BPV-1 E2 proteins. Qauthier and 
coworkers (10) probed the structure of HPV-16 E2 with poly­
clonal antibodies raised against synthetic peptides that cover 
the whole region of the HPV-16 E2 protein. They found that 
antipeptide antibodies against the hinge region but not against 
the transactivation domain or the DNA-binding and dimeriza­
tion domain were able to recognize the native form of the 
HPV-16 E2 protein. 
In our study, MAb 1E2 (epitope within residues 184 to 190) 
was able to recognize neither E2-DNA nor El-E2-origin com­
plexes in a mobility shift assay. Curiously, deletion of the first 
alpha helix from the BPV-1 E2 protein revealed the epitope 
for MAb 1E2, and the protein in the protein-DNA complex 
was recognized by the antibody. Thus, the epitope for this 
MAb is probably buried within the compact structure of the 
N-terminal domain and is not accessible unless the structure of 
the molecule is distorted in some fashion. These data suggest 
that the transactivation domain of the E2 protein, unlike many 
other transactivation domains, has remarkable structural in­
tegrity. As shown by X-ray analysis, the C-terminal DNA-
binding and dimerization domain has a compact structure (15). 
Deletion of the last 13 C-terminal residues of E2 resulted in an 
inactive protein unable to bind DNA and support replication 
(21a). So, our data confirm that in a native context, both the 
transactivation domain and the DNA-binding and dimeriza­
tion domain of BPV-1 E2 have a complex and relatively rigid 
structure, while the central, hinge region is highly mobile and 
flexible. 
MAb 5H4 and its Fab' fragment efficiently inhibited the 
formation of both E2-DNA and El-E2-origin complexes. They 
not only competed with DNA for binding but also were able to 
dissociate the preformed E2-DNA complex. In a transient rep­
lication assay, MAb 5H4 and its Fab' fragment efficiently sup­
pressed BPV-1 DNA replication. This assay is another way to 
demonstrate that the BPV-1 E2 protein interaction with the 
specific recognition sequence within an origin of replication is 
essential for the initiation of viral DNA replication. In addi­
tion, the results indicate that it is possible to target the E2 
protein interaction with DNA for therapeutic purposes by us­
ing this specific MAb or Fab' fragment to block the replication 
of papillomaviruses. 
In our study, MAb 3F12 (epitope at residues 199 to 206), 
directed against the last 10 amino acids of the transactivation 
domain, and MAbs that bind the hinge region, 1H10 (epitope 
at residues 208 to 218) and 1E4 (epitope at residues 250 to 
280), efficiently suppressed BPV-1 DNA replication. However, 
the Fab' fragments of 1H10 and 3F12 had no inhibitory effect 
on and even activated replication. None of these antibodies 
interfered with the formation of the El-E2-origin complex. 
These data suggest that antibodies 3F12 and 1H10 sterically 
hindered the inter- or intramolecular interactions required for 
the replication activity of the E2 protein. On the other hand, 
our results demonstrate the importance of the hinge region for 
the replication activity of the E2 protein. This hypothesis is 
based on results from several laboratories. E2 proteins con­
taining large internal in-frame deletions of the hinge region 
(from amino acids 195 to 309,213 to 309, and 220 to 309) were 
not able to support DNA replication (or had a decreased 
efficiency) but could efficiently enhance the binding of El to 
the replication origin (46, 47). A fusion protein which con­
tained the transactivation domain together with the hinge re­
gion of BPV-1 E2 linked to the GCN4 DNA-binding domain 
supported replication much more efficiently than a fusion pro­
tein in which only the transactivation domain of E2 was linked 
to the GCN4 DNA-binding domain (3). These data suggest 
that the conformational freedom of the E2 protein is impor­
tant for its role in replication and that the inhibitory effect of 
the antibodies against the epitopes in the hinge region as well 
as in the very last part of the transactivation domain may be 
explained by interference with conformational freedom, which 
would not allow E2 to assume the proper conformation re­
quired for its replication activity. However, another possibility 
is that this region is important for interactions with replication 
factors, so that antibodies that bind to the first part of the hinge 
region can but Fab' fragments cannot prevent the binding of 
replication factors to the same region of the E2 protein. 
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Abstract 
The bovine papillomavirus type-1 E2 protein is the master regulator of the papillomavirus transcription and 
replication, the activity of which is regulated through sequence-specific DNA binding. Peptide nucleic acid (PNA) is 
a nucleic acid analogue, which associates with high affinity to complementary DNA, RNA or PNA, yielding in 
formation of stable complexes. The potential use of PNA as a sequence-specific inhibitor of the E2 protein activity 
is studied in this report. We demonstrate that replacement of one or both DNA strands with the complementary PNA 
reduced drastically the affinity of the BPV-1 E2 protein to its target site in the direct as well as in competitive binding 
as shown by in vitro gel-shift assays. We demonstrate that PNA could specifically bind to the double stranded E2 
binding site by forming the complex with DNA oligonucleotide. In addition, PNA was able to bind specifically to the 
E2 binding site within the supercoiled plasmid DNA. Such binding of PNA to the E2 binding site within the origin 
of replication specifically abolished the activity of the E2 protein in the initiation of DNA replication in vivo. © 1999 
Elsevier Science B.V. All rights reserved. 
Keywords: Papillomavirus; E2 protein: Peptide nucleic acid (PNA); Replication 
1. Introduction 
Bovine papillomavirus type 1 (BPV-1) has been 
studied extensively as a model for papillomavirus 
replication and transcription. The viral E2 protein 
is the master regulator of the viral life cycle, it 
modulates the transcription of viral genes 
* Corresponding author. Tel.: + 372-7-375047; fax: 4-372-
7-420286. 
E-mail address: ustav@ebc.ee (M. Ustav) 
(Spalholz et al., 1985), is responsible for initiation 
of DNA replication (Ustav and Stenlund, 1991; 
Yang et al., 1991), for stable maintenance of the 
viral genome (Piirsoo et al., 1996) and for chro­
matin association of the viral genome in the nu­
cleus (Lehman and Botchan, 1998; Skiadopoulus 
and McBride, 1998; lives et al., 1999). For the 
initiation of papillomavirus DNA replication, two 
virus-encoded proteins, El and E2 are required 
(Ustav and Stenlund, 1991). The papillomavirus 
El protein is the viral helicase that initiates viral 
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DNA replication. The E2 protein is required for 
recruitment of the El replication protein to the 
papillomavirus origin of replication (Mohr et al., 
1990; Lusky et al., 1994; Seo et al., 1993; Sedman 
and Stenlund, 1995). E2 is the sequence-specific 
DNA-binding protein which binds as a dimer to 
the 12-bp palindromic sequence (ACCN6GGT), 
several copies of which are found in the viral 
enhancer sequences (Androphy et al., 1987). The 
protein consists of an N-terminal transcription 
activation domain and a C-terminal DNA binding-
dimerization domain, connected by a central hinge 
region (Giri and Yaniv, 1988). The crystal struc­
ture of the DNA binding-dimerization domain of 
E2 has been determined and has revealed a dimeric 
DNA binding-dimerization motif (Hegde et al., 
1992). 
Peptide nucleic acids (PNAs) are oligonucleotide 
analogues in which the deoxyribose phosphate 
backbone has been replaced by non-charged N-(2-
aminoethyl)glycine polymer (Nielsen et al., 1991). 
PNAs can bind to single-stranded DNA or RNA 
via Watson-Crick base-pairing, with binding 
affinities significantly higher than those of the 
corresponding DNA oligomers (Egholm et al., 
1993). With duplex DNA, PNA interacts to form 
strand-invasion complexes, which has been de­
scribed in terms of the following 'binding rules': (1) 
homopyrimidine PNAs invade dsDNA to form 
PNA2-DNA triplex structures; (2) purine rich 
PNAs can invade dsDNA via PNA-DNA du­
plexes; and (3) cytosine rich pyrimidine PNA.S can 
interact directly with dsDNA to form PNA-
DNA2 triplexes (Peffer et al., 1993; Demidov et al., 
1995; Wittung et al., 1997). These high affinity 
interactions of PNA and, additionally, very high 
stability of PNA polymers in biological systems 
(Demidov et al., 1994), makes this new class of 
biopolymers very attractive as a potential candi­
date for reagents suitable for regulation of gene 
expression. Binding of PNA to dsDNA target 
interferes with the binding of proteins which also 
recognise this target. For instance, cleavage of 
DNA by restriction enzymes is inhibited if the 
restriction enzyme recognition sequence is occu­
pied by PNA (Hanvey et al., 1992; Nielsen et al., 
1993). In vitro studies have demonstrated that 
PNA-dsDNA complexes are efficient inhibitors of 
transcription elongation and also completely abol­
ish binding of transcription factors to their recog­
nition sequence and thereby inhibit transcription 
initiation (Nielsen et al. 1994; Vickers et al., 1995). 
In the viral context the activity of viral genes as 
well as the initiation of replication are regulated 
through regulation of E2 activity (for review Ustav 
änd Ustav, 1998). For example, the truncated 
forms of E2 containing the DNA-binding domain 
only can act as repressors. Both competitive DNA 
binding at the E2BS and formation of het-
erodimers have been proposed as potential mecha­
nisms by which the repressor molecules inhibit E2 
(Lim et al., 1998). Recently, we have shown that 
monoclonal antiboby and its Fab' fragment di­
rected against the C-terminal part of the protein, 
capable of inhibiting the formation of E2-DNA 
complex efficiently suppressed the BPV-1 DNA 
replication in vivo (Kurg et al., 1999). These data 
suggest that the E2 protein can serve as a viable 
target for the development of therapeutics against 
papillomaviruses and compounds, which interfere 
with E2 binding to DNA are promising candidates 
for that. Using an NMR-based screening method, 
a chemical compound [5-(3'-(3",5"-dichlorophe-
noxy)-phenyl)-2,4-pentadienoic acid] was found to 
inhibit the binding of E2 to DNA (Hajduk et al., 
1997), however, it is not known whether this 
compound is able to interfere with the E2 protein 
activity in vivo, too. In the present study, we have 
assessed the ability of PNA to specifically interfere 
with the E2 protein binding to its recognition 
sequence. We demonstrate that specific comple­
mentary PNA was able to form a sequence-specific 
complex with the E2 binding site (E2BS) and that 
occupying of E2 target site by PNA prevented the 
E2 protein binding to its target site. In addition, 
binding of PNA to the E2 binding site within the 
origin of replication specifically abolished the ac­
tivity of the E2 protein in the initiation of DNA 
replication in vivo. 
2. Materials and methods 
2.1. Synthesis of PNA 
Three PNA polymers, PNA1 (TCGACCG-
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GCAACGGTACT amide), PNA2 (AGCTGGC-
CGTTGCCATGA amide) and PNA3 (CC-
CTCGCTGAGGTTC amide) were synthesised 
from the following monomers obtained from Mil-
lipore, USA: r-Boc-PNA-T, f-Boc-PNA-(Z)A, r-
Boc-PNA-(Z)C, r-Boc-PNA-(Z)G. The PNAs 
were synthesised in a stepwise manner in a 0.03 
mmol scale manually on solid support (p-methyl-
benzhydrylamine resin to obtain C-terminal 
amides) using 2-(lH-benzotriazole-l-yl)-l,l,3,3-te-
tramethyluronium tetrafluoroborate (TBTU) acti­
vation strategy. The PNA polymers were finally 
cleaved from the resin with liquid HF at 0°C for 
30 min as described earlier (Langel et al., 1992). 
The purity of the PNA polymers was > 99% as 
demonstrated with HPLC on an analytical Nu-
cleosil 120-3 C|8 reverse-phase HPLC-column (0.4 
cm x 10 cm). Molecular mass of each synthetic 
PNA polymer was determined with a Plasma Des-
orption Mass Spectrometer (Bioion 20, Applied 
Biosystems), and the calculated values were ob­
tained in each case. 
2.2. Plasmids 
BPV-1 El expression vector pCGEag and E2 
expression vector pCGE2 have been described in 
(Ustav and Stenlund, 1991) and replication re­
porter plasmids pUCAlu, Msp(7914-27), Mspl5 
and Mspl5BS9 in (Ustav et al., 1991, 1993). 
2.3. PNA binding assays 
The buffer used throughout this study was TE 
(10 mM Tris-HCI and 1 mM EDTA pH 7.6). 
The duplexes between PNA-PNA and PNA-
DNA were formed by mixing equimolar 
amounts or 1 to 10 for DNA-PNA hybrid of 
the strands and annealing at 37°C for 1 h. To 
form DNA-PNA hybrid duplex DNA oligo 
5'GATTCC GTACCGTTGCCGGTCG 3' com­
plementary to PNA1 sequence was used. When 
required, the DNA oligo was end-labelled by us­
ing T4 polynucleotide kinase and [y-32P]ATP. 
PNA binding to the dsDNA was measured by 
using the gel mobility shift assay. A fixed con­
centration of the end-labelled duplex DNA (1.4 
nM) was incubated with increasing concentra­
tions of the PNA in TE with or without 150 
mM NaCl in the final volume of 10 |il. Follow­
ing the incubation at 37°C for 2 h or at 70°C 
for 10 min and at 37°C for 30 min, PNA bound 
duplex DNA was separated from free target by 
electrophoresis through an 8% native Polyacry­
lamide gel (80:1 acrylamide:N,N-methylene-
bisacrylamide) in 0.25 x Tris-borate-EDTA 
(TBE) for 2 h at 100V. Gels were fixed in acetic 
acid/ethanol, dried and exposed to X-ray film. 
Quantitative analysis was carried out with a 
Phospholmager SI (Molecular Dynamics). 
To examine the inhibition of binding of the 
E2 protein, PNA was first complexed with target 
DNA in TE as described above, then the buffer 
conditions were adjusted to E2 binding buffer 
(10 mM Tris-HCI, pH 7.5, 100 mM KCl, 2 
mM DTT, 0.5 mM PMSF, 15% glycerol, 5 mg/ 
ml BSA, 1 (ig/ml leupeptine, 1 ng/ml aprotinine) 
and 1 ng of the purified E2 protein and 1 ng of 
non-specific competitor salmon sperm DNA 
were added. After a 15 min incubation at room 
temperature, E2-DNA complex and PNA-
DNA complex were separated from free target 
by electrophoresis through a 6% native Polyacry­
lamide gel as described above. 
For the replication assay, 100 ng of reporter 
plasmid was incubated overnight with increasing 
concentrations of PNA in 10 nl TE at 37°C. 
2.4. Detection of PNA-plasmid complexes in vitro 
Biotinylated-PNAl (300 nM) was allowed to 
bind to different replication reporter plasmids 
(lOOng in each case) in 15 nl TE at 37°C 
overnight or at 8CC for 10 min and at 37°C for 
1 h. The reactions were analyzed by 1% agarose 
gel electrophoresis. Blotting of gels was done by 
the semidry-blotting method using the Trans-
blot11 SD electrophoretic transfer unit (Bio-Rad) 
at a fixed current (mA) of 2 x the gel surface 
area (cm2) for 1 h. For transfer, polyvinylidene 
difluoride (PVDF) membrane (Boehringer 
Mannheim) was activated in methanol and then 
wetted in water, filter papers (Whatman 3MM) 
were equilibrated in transfer buffer (48 mM Tris/ 
39 mM glycine/20% methanol, pH 8.5) (Demczuk 
4 R. Kurg et al. / Virus Research 000 (1999) 000-000 
et ai., 1993). For biotin detection, membranes 
were first blocked for 30 min in Tris-buffered 
saline (TBS) supplemented with 0.2% Tween 20. 
Antibody, streptavidin-horseradish peroxidase 
conjugate (Amersham) was applied at a dilution 
of 1:2500, and enhanced chemiluminescence de­
tection was done using the ECL + Plus detection 
kit (Amersham) according to the manufacturer's 
recommendations. 
2.5. Cell culture and replication assay 
CHO cells were cultured in Fl2 medium sup­
plemented with 10% fetal bovine serum. For 
transfection CHO cells were trypsinized, har­
vested by centrifugation and resuspended in F12 
medium containing 10% FCS at a density of 
lxlO7 cells/ml. 200 jj.1 of cell suspension was 
mixed with pre-formed plasmid-PNA complex, 
100 ng of plasmid pCGE2, 250 ng of plasmid 
pCGEag and 50 ng of salmon sperm DNA in a 
disposable electroporation cuvette and was sub­
jected to an electric discharge of 230V using a 
BioRad Gene Pulser at 970 nF capacity. After 
the discharge cell/PNA/DNA mixture was left at 
room temperature for 15 min, then cells were 
washed, divided between two 60 mm plates and 
plated in F12 supplemented with 10% FCS. 
Cells were harvested either 48 or 72 h after elec­
troporation. 
Transient replication assay was carried out as 
described by Ustav and Stenlund (Ustav and 
Stenlund, 1991). Briefly, an episomal DNA was 
extracted by alkaline lysis, purified, digested with 
Dpnl and linearizing enzyme Hindlll and ana­
lyzed by Southern blotting. 
3. Results 
A. 
E2BS 5* GATTCCGTACCGTTGCCGGTCG 3' 
dsDNA 3' GCATGGCAACGGCCAGCCTAG 5' 
PNA1 TCGACCGGCAACGGTACT amide 
PNA2 AGCTGGCCGTTGCCATGA amide 
PNA3 CCCTCGCTGAGGTTC amide 
B. 
Alu Msp 
7891 I I 7914 
E2BS11\ A/T rich 
I \reglon 
7947/1 15 
Alu 
54 
E1BS/ E2BS12 
ACCATCACCGTT 
Alu 
Msp(7914-27) I —t 
Msp15 E2BS9 ' ' 
Msp15BS9 I |2Qbpj 1 
ACCGTTGCCGGT 
Fig. 1. Schematic representation of E2 binding site, PNAs and 
papillomavirus Ori constructs used in this study. (A) Oligonu­
cleotide and PNA sequences. The E2 binding site is shown in 
block letters. The PNA-s are oriented from the N to the C 
terminus (the C terminus is a carboxy-amide) such that when 
the N-terminal end of the PNA faces the 5' end of the 
oligonucleotide the complex is termed parallel. (B) Schematic 
representation of the BPV-1 replication origin inserts used. 
Numbers indicate positions on the BPV-1 nucleotide sequence. 
3.1. Interaction of the BPV-1 E2 protein with 
PN A-DNA hybrid 
The BPV-1 E2 protein is a transactivator, 
which binds specifically an interrupted palin­
dromic sequence ACCG(N4)CGGT (Androphy 
et al., 1987). PNA has been found to be a good 
DNA mimic in terms of its ability to form Wat­
son-Crick base-paired helical duplexes with 
complementary oligonucleotides (Egholm et al., 
1993). In PNA only the nucleobases of DNA 
are retained and the backbone of PNA is non-
charged. Therefore, the study of interaction of 
DNA binding protein with PNA containing du­
plex could provide valuable information about 
the relative contributions of the nucleobases by 
excluding the electrostatic interaction with back­
bone. To test whether the E2 protein is able to 
bind specifically to PNA-DNA hybrid or 
PNA-PNA duplex, two PNA 18-mers (PNA1 
and PNA2) were designed to mimic the E2 
protein binding site (E2BS) (Fig. 1A). The du­
plexes between PNA1-PNA2 and ssDNA-
PNA1 were formed by mixing equimolar 
amounts (or 1 to 10 for DNA-PNA hybrid) of 
the strands and annealing for 1 h in 10 mM 
Tris-HCl ImM EDTA (TE). In order to deter-
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Fig. 2. The ability of the BPV-1 E2 protein to bind PNA-DNA 
hybrid and PNA-PNA duplex. (A) The mobility shift assay 
was carried out with 1 ng of E2, 1 nM of end-labelled E2BS 
and various concentrations of pre-formed, non-labelled ds­
DNA.. PNA-DNA hybrid or PNA-PNA complex for 1 h at 
room temperature. Protein-DNA complex was resolved on 
6% PAGE in 0.25 x Tris-borate-EDTA. (B) Quantitation of 
data from Fig. 2A. The values shown are the results of three 
independent experiments. 
mine the interaction between the E2 protein and 
PNA containing hybrids, a competition assay was 
used. The BPV-1 E2 protein forms a specific 
complex with E2BS which could be detected in 
the gel-shift assay (Fig. 2A, line 1). Adding of 
pre-formed non-labelled dsDNA, PNA-DNA hy­
brid or PNA-PNA duplex to the reaction mix­
ture containing the E2 protein and labelled E23S 
would interfere with the E2-E2BS complex for­
mation in case, if these compounds would be able 
to compete for the binding to E2 with the labelled 
E2BS. As shown in Fig. 2A, lines 2-4, the forma­
tion of the E2-DNA complex was efficiently in­
hibited by an excess of the nonlabelled specific 
oligonucleotide. Addition of 1.4 nM non-labelled 
oligonucleotide reduced the detectable E2 binding 
considerably, which was virtually undetectable at 
70 nM of non-labelled E2BS. Replacing one 
strand in dsDNA target with PNA, or in the case 
of PNA-PNA duplex, the considerable decrease 
in the formation of specific E2-DNA complex 
was not observed even at the highest concentra­
tions studied (100 nM) (Fig. 2A, lanes 5-12, Fig. 
2B). 
We also studied the ability of the E2 protein to 
interact with the PNA-DNA hybrid (directly) by 
gel-shift assay. In this case, the end-labelled ss-
DNA oligo was first incubated with complemen­
tary PNA1 (molar ratio 1:10) in TE for 1 h at 
37°C. Following pre-incubation the buffer condi­
tions were adjusted to E2-DNA binding buffer 
and increasing concentrations of purified E2 were 
added. After 45 min at 37°C the reaction was 
visualised by electrophoresis. We were not able to 
detect any specific E2:PNA-DNA band under 
our assay conditions used in this case as well 
(data not shown). Thus, the E2 protein was un­
able to form specific and stable complex with 
either PNA-DNA hybrid or PNA-PNA duplex. 
3.2. PNA binding to E2 binding site 
PNA molecules can bind duplex DNA to form 
specific and stable PNA-DNA strand-invasion 
complexes (Peffer et al., 1993; Demidov et al., 
1995; Wittung et al., 1997). To study the PNA 
binding to E2 binding site (E2BS), the radiola­
beled dsDNA was complexed with PNA and the 
resulting complex was separated from free DNA 
by electrophoresis in 8% Polyacrylamide gel, and 
the intensities of both bands were quantified. 
First, E2BS was incubated at various concentra­
tions of specific PNA1, PNA2 or non-specific 
PNA3 in TE for 10 min at 70°C and for 30 min at 
37CC. Incubation at 70°C was performed in order 
to melt the dsDNA E2BS and to stretch out the 
PNA, as PNAs used in this study contain inter­
rupted palindromic sequences that might form 
20 
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relatively stable intramolecular hairpin structures. 
As shown on Fig. 3A (lanes 2-6) and Fig. 3B, 
binding of specific PNAl to target dsE2BS was 
first detectable at the concentration of 0.2 nM and 
PNA 1 PNA 2 
- <3 T, <b Or sy Q- <v <o o- <5- <ay <v 
"**•1 
9 10 11 12 13 14 15 16 
HM[PNA] 
_ PNA-DNA 
complex 
•^-dsDNA 
c. 
100 
1 2 3 4 5 
JIM[PNA;| 
-PNAl 
-PNA2 
-PNA3 
-PNAi+ISOmM N»CI 
0 1 2 3 4 5 6 7 
jiM [PNA] 
Fig. 3. The ability of PNA-s to bind E2 binding site. (A) A 
fixed concentration of the end-labelled duplex E2BS (1.4 nM) 
was incubated with increasing concentrations of each PNA in 
TE for I0 min at 70"C and after that for 30 min at 37°C. The 
samples were analysed by electrophoresis in a 8% Polyacry­
lamide gel, followed by autoradiography. PNA binding gener­
ates a complex of reduced mobility relative to the duplex. (B) 
Quantitative analysis of Fig. 3A. (C) The ability of PNA-s to 
bind E2BS for 2 h at 37°C. The values shown are the results of 
three independent experiments. 
reached 83% at 2 jaM and 93% at 6 nM. Binding 
of PNA2, which had a parallel orientation relative 
to the target was less efficient reaching only 51% 
at 6 nM (Fig. 3A, lanes 7-11, and Fig. 3B). 
Binding of non-specific PNA3 to E2BS was not 
observed at these concentrations (Fig. 3A, lanes 
12-16, and Fig. 3B). Fig. 3C shows the data 
Obtained when the binding reaction was carried 
out for 2 h at 37°C without preceding incubation 
at 70°C as the formation of a complex between 
PNA and DNA should also open the hairpin 
structure of the PNA (Armitage et al., 1998). 
Under these conditions, binding of PNAl to 
E2BS started at the concentration of 0.6 pM and 
reached 91% at 6 nM, whereas binding of PNA2 
reached only 20% at 6 nM. So, we conclude from 
these results that PNA is able to specifically bind 
to E2BS and that separation of strands at higher 
temperature enhances the complex formation. The 
binding of PNA to DNA is highly dependent on 
salt concentration (Peffer et al., 1993). The in­
crease of the salt concentration would make a 
DNA structure more compact, which would make 
it more difficult for PNA to invade the dsDNA 
structure and form sequence-specific complex. In 
our experiments a decrease in binding of PNA to 
DNA at higher NaCl concentrations was also 
observed. At physiological salt concentrations 
(150 mM NaCl) the binding of PNAl was re­
duced approximately twice-only 45% binding (6 
nM PNAl, 2h incubation at 37°C) was observed 
to E2BS (Fig. 3C). 
Sequence-specific DNA binding is essential for 
the expression of most of the functional activities 
of the E2 protein. Therefore we have studied the 
ability of the E2 protein to bind to E2BS which is 
in complex with PNA. First, specific PNAl was 
pre-incubated with E2BS in TE due to the slow 
kinetics of invasion in the higher salt buffer. After 
a 2 h pre-incubation at 37°C the buffer conditions 
were adjusted to E2 binding buffer and the 
purified E2 protein was added. The amount of E2 
bound in the presence of increasing concentra­
tions of PNA was visualized by gel-shift (Fig. 4). 
The BPV-1 E2 protein specifically binds E2BS 
(lane 7). PNAl, which is complementary to the 
upper strand of E2BS, effectively inhibited the 
binding of E2 to its target site at the concentra-
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Fig. 4. Effect of PNA-s on the E2 protein binding in vitro. 
E2BS was pre-incubated in TE buffer with PNA at the indi­
cated concentrations for 2 h at 37°C. Following the preincu­
bation, buffer conditions were adjusted to E2 binding buffer 
and 1 ng of the purified E2 protein was added. After 15 min 
incubation, E2-DNA complex and PNA-DNA complex were 
separated from free target by electrophoresis through a 6% 
native Polyacrylamide gel. 
tion of 6 nM of PNA (lane 3). As a control, 
non-specific PNA3 had no effect on E2 binding at 
any concentration tested (lanes 4-6). These data 
demonstrate that complementary PNA is able to 
specifically bind to the E2BS and that this com­
plex results in the specific disruption of the E2 
binding to its target site. 
3.3. Inhibition of BPV-1 ori replication by PNA 
in vivo 
The viral E2 protein is required for the initia­
tion of papillomavirus DNA replication in vivo 
(Ustav and Stenlund, 1991). The function of E2 in 
replication is to serve as a specificity factor en­
hancing binding of the viral helicase El to the 
origin of replication (Yang et al., 1991; Seo et al., 
1993; Ustav et al., 1993; Sedman and Stenlund, 
1995). So, next we looked at the ability of PNA to 
block the E2 protein dependent BPV-1 origin 
replication by inhibiting E2 binding to its target 
site. First we investigated PNA binding to differ­
ent replication reporter plasmids. Ori constructs 
used in this study are shown on Fig. IB and 
described elsewhere (Ustav et al., 1991, 1993). 
Biotinylated-PNAl was incubated with various 
reporter plasmids in TE and the resulting com­
plexes were separated in a standard agarose gel-
electrophoresis (Fig. 5A, left image) and then 
transferred by electroblotting to the PVDF mem­
brane. Immunodetection of biotin revealed the 
specific PNA-plasmid complexes as well as un­
bound PNA, appearing at the top of the lanes 
(Fig. 5A, right image). The best binding was 
observed to artificial Ori construct Mspl5BS9, 
where a strong E2 binding site BS9 is linked to 
A/T rich region and El BS (Fig. 5 A, lane 10). 
PNAl has a perfect match with E2BS9, whereas 
there are 3 mismatches out of 12 in the middle of 
the target sequence in the case of E2BS11 and 4 
mismatches out of 12 in the case of E2BS12. 
Under our assay conditions, PNAl binding to 
Alu fragment, which contains E2BS11 and 
E2BS12 (Fig. 5A, lane 8) and a slight binding to 
Msp(7914-27) containing E2BS12 only (Fig. 5A, 
lane 9) was observed. A weak binding to a nega­
tive control Mspl5, which does not contain any 
E2BS near the El binding site (lane 7), was 
probably due to E2 binding motif present in the 
plasmid pUC!9 backbone. 
In the following experiments different replica­
tion reporter plasmids (100 ng of each) were 
pre-incubated at various concentrations of PNA 
in TE buffer at 37°C overnight. After that the 
PNA-plasmid complexes were co-transfected to­
gether with expression plasmids for E2 (pCGE2) 
and for El (pCGEag) into CHO cells as described 
in Section 2. Fortyeight and 72 hours after elec-
troporation the episomal DNA was extracted by 
alkaline lysis, purified, digested with Dpn I and 
linearizing enzyme tf/ndlll, and analysed by 
Southern blotting as described earlier (Ustav and 
Stenlund, 1991). In all cases, inhibition of the 
replication was dependent on the concentration of 
specific PNA (Fig. 5B). When tested at concentra­
tions of 6 |iM or less the E2BS specific PNAl 
failed to inhibit replication of the BPV-1 origins 
in the cells. However, at a concentration of 300 
nM specific PNAl inhibited the replication of 
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artificial origin Mspl5BS9 and papillomavirus 
minimal origin pUCAlu completely (Fig. 5B and 
C, lanes 11-12). At the same time the control 
PNA, non-specific PNA3, had no effect on pU­
CAlu on replication (Fig. 5C, lanes 21-22 and 
Fig. 5B). A slight inhibition of replication of Ori 
construct Msp(7914-27) with 300 jiM of PNAl 
was also observed (Fig. 5B). The concentration of 
PNA of 300 nM in the reaction mixture (which 
was diluted 20 x during the electroporation) was 
not toxic to the cells and had no effect on the cell 
growth (data not shown). We also tested the 
^ J" & ' ^ & & 
+ + + + PNA1 + + + h 
1 2 3 4 5 8 9 10 
c. 
PNA1 PNA3 
0.06 0.6 60 300 0.06 0.6 60 300 <f ^ -
'$> <v' 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 1 2 3 4 5 6 
M*p15BS9 
Map(7914-27) Mi (PWA3) 
8 0-4 * 
100 200 300 
|iÄ! [PNA] 
Fig. 5. 
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ability of PNA to inhibit the replication of papil­
lomavirus origin in the cells without pre-forming 
the complex of PNA with pUCAlu plasmid. In 
this case, plasmids pUCAlu, pCGE2, pCGEag 
and PNA were mixed in the electroporation cu­
vette and immediately co-transfected into CHO 
cells. However, in this case we could not observe 
any inhibition of replication of papillomavirus 
origin plasmid pUCAlu (Fig. 5D). 
4. Discussion 
Molecular interaction between proteins and 
DNA constitute the basis for specific regulation of 
key biological functions such as gene expression, 
transcription and replication. Therefore molecules 
that bind DNA in a sequence-specific manner are 
attractive candidates as tools for modulation of 
these activities and have the potential, at a later 
stage, to be exploited as pharmaceuticals. In the 
present study we have investigated the potential 
application of the specific peptide nucleic acid 
(PNA) as anti-viral agent against 
papillomaviruses. 
In this study, we show that the BPV-1 E2 
protein is not able to bind specifically either 
PNA-DNA hybrid or PNA-PNA duplex. The 
interaction of double stranded DNA with protein 
is often divided into contributions from the nega­
tively charged desoxyribose phosphate backbone 
and the nucleobases themselves. In the PNA, only 
the nucleobases of DNA are retained, the back­
bone is replaced by uncharged polyamide chain. 
As phosphate contacts largely contribute to the 
DNA-binding affinity of E2 protein (there are 20 
direct and 28 water-mediated phosphate interac­
tions per complex) (Hegde et al., 1992), it is not 
surprising that the E2 protein binds the PNA-
DNA hybrid with dramatically reduced efficiency. 
The sequence-specific DNA binding is often ac­
companied by deformation of the DNA. The 
DNA within the E2/E2BS complex adopts a 
43°C bend towards the minor groove at the centre 
of the target (Hegde et al., 1992) and recently it 
has been shown that BPV E2 protein binding 
affinity depends on DNA flexibility (Hines et al. 
1998; Rozenberg et al., 1998). So, the origin of the 
reduced binding of E2 to PNA-DNA hybrid may 
also result from the decreased flexibility of the 
pseudopeptide backbone. Therefore, although 
structure determinations of PNA-DNA duplexes 
have suggested that PNA adopts to its nucleic 
acid partner without contributing significantly to 
the final conformation of the structure (Eriksson 
and Nielsen, 1996) we can not exclude the possi­
bility that some conformational rigidity of the 
structure of PNA-DNA hybrid does not allow 
protein binding. 
In vitro binding experiments using a radiola­
beled E2BS demonstrated that binding of PNA 
to duplex DNA was sequence specific and that the 
orientation of the PNA relative to the DNA was 
important. Our results also show that preceding 
separation of DNA strands and linearization of 
PNA enhanced the formation of PNA-DNA 
complex in vitro. Stable PNA-DNA complexes 
have so far been demonstrated for homopyrim-
Fig. 5. Effect of PNA on BPV-1 origin replication. (A) Detection of the PNA and DNA components of the PNA-plasmid complex. 
Biotinylated-PNAl (12 ng) was incubated with 100 ng of various papillomavirus replication origins in TE at 37°C overnight. The 
resulting complexes were separated in a standard agarose gel-electrophoresis (lanes 1-5) and then transferred by electroblotting. 
(Lanes 6-7) Immunodetection of biotinylated-PNA on PVDF membrane. (B) Effect of PNA-s on different BPV-1 origin replication. 
Reporter plasmids were pre-incubated with indicated concentrations of PNA in TE buffer overnight at 37°C. The plasmid-PNA 
complexes were then electroporated into CHO cells as described in Section 2. Episomal DNA was extracted from cells 48 h after 
transfection. digested with Dpn 1 and linearizing enzyme HindlU and analyzed by Southern blotting. The replication signals of three 
independent experiments were quantified with a Phosphoimager, and signals from cells transfected with the origin-containing 
plasmids only were used as a control to normalize the results. (C) Southern blot analysis of transient replication of the BPV-1 origin 
plasmid pUCAlu in the presence of various concentrations of PNA. Reporter plasmid pUCAlu was pre-incubated with indicated 
concentrations of PNA in TE buffer overnight at 37°C. The plasmid-PNA complex was then electroporated into CHO cells, 
episomal DNA was extracted from cells either 48 or 72 h after transfection. Filters were probed with radiolabeled pUCAlu plasmid. 
M- marker, 100 pg of reporter plasmid pUCAlu. (D) Southern blot analysis of transient replication of the BPV-1 origin plasmid 
pUCAlu in the presence of 12 jag of PNA. In this case, DNA and PNA were mixed before co-transfection into CHO cells. 
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idine PNA-s binding to homopurine targets, how­
ever, PNA binding to DNA with only 66% A + G 
content has also been shown (Gambacorti-
Passerini et al., 1996). There are distinct mecha­
nistic variations how PNA interacts with the 
dsDNA target depending on nucleobases (Wit-
tung et al., 1997). For example, cytosine-rich 
PNA oligomers are added to the double-stranded 
target polynucleotides as Hoogsteen strands, 
forming PNA-DNA2 triplex structures, but the 
homopurine PNAs, as well as alternating T/G 
PNA oligomer, are instead found to invade their 
DNA targets, forming new PNA-DNA com­
plexes. In our study, the specific PNAl had a 
mixed sequence with 50% T + C content and it is 
difficult to say what kind of PNA-DNA complex 
was formed. However, PNA binding to E2BS was 
temperature and salt dependent, which shows that 
this reaction requires DNA 'breathing', we sug­
gest that PNA binding caused at least partial 
strand exchange resulting in PNA-DNA-DNA 
triplex. The fact that PNAl and PNA2, but not a 
control PNA3, form the complex of the same size 
without releasing single strand oligonucleotide 
suggests that in our cases PNA forms a complex 
with the dsDNA. Whatever the precise structure, 
the PNA binds to the dsDNA with sufficient 
affinity to specifically prevent binding of the E2 
protein to its target site. However, PNA was able 
to inhibit E2 binding in vitro under certain condi­
tions. We were not able to demonstrate specific 
activity when the PNA binding was performed in 
E2 binding buffer, which had a KCl concentration 
of 100 mM. Specific activity was observed when 
PNA was incubated with the DNA target in low 
salt buffer prior to addition to the E2 binding 
buffer. In this case, binding of PNA to its duplex 
target correlated with inhibition of E2 binding. As 
binding to its target site is required for expression 
of all the activities of E2, these findings open the 
possibility to use PNA as a tool in research. 
The main objective of this work was to deter­
mine whether PNA binding to E2BS results in 
specific inhibition of papillomavirus replication in 
a cell culture model. Specific inhibition was ob­
served when PNA was incubated with origin con­
taining plasmids in buffer with low salt 
concentration prior to electroporation. Specific 
PNA bound effectively to On construct 
Mspl5BS9 and poorly to BS 12 within origin 
Msp(7914-27). PNA binding resulted in strong or 
weak inhibition of replication, respectively. In the 
case of reporter plasmid pUCAlu, which contains 
E2BS11 and E2BS12, a weak binding of PNAl 
was observed. This result was not unexpected as 
both binding sites have a considerable homology, 
although contain mismatches comparing with 
PNAl. Suprisingly, binding of PNA to both E2BS 
with low efficiency resulted in strong inhibitory 
effect in replication assay. Recently it was shown 
that E2BS11 and E2BS12 play separate but syn-
ergetic roles in the initiation of BPV DNA repli­
cation that are dependent on their location within 
the origin (Gillette and Borowiec, 1998). Our 
present results support this hypothesis as partial 
blocking of both sites by PNA resulted in syner­
gistic response of viral DNA replication. 
We were not able to detect any specific in­
hibitory effect when PNA was mixed with the 
plasmid pUCAlu and electroporated into the cells 
without pre-forming PNA-plasmid complex. 
Probably this was due to decreased binding of 
PNA to DNA at physiological salt concentra­
tions, which was observed in our in vitro binding 
experiments, and has been shown earlier, as well 
(Peffer et al., 1993; Vickers et al., 1995). However, 
once formed, the PNA-DNA complexes are all 
very stable at physiological salt concentrations 
(Chemy et al., 1993; Wittung et al., 1997). In our 
experiments, once formed, the PNA-plasmid com­
plex was sufficiently stable to produce an effect 
even 120 h after electroporation. On the other 
hand, compartmentalisation of PNA to the nu­
cleus (if it is not bound to plasmid prior to 
electroporation) could not be sufficient for forma­
tion of the PNA-DNA complex and thereby 
achieving the inhibitory effect. In addition, the 
accessibility of the E2 binding site to the specific 
PNA in vivo may also reduce its efficiency of 
binding. 
In the present study, we have targeted the E2 
protein for anti-viral agent against papillo­
maviruses. PNA-s have a potentional as antiviral 
chemotherapeutic agent, especially in view of the 
fact that PNA-s are extremely stable to digestion 
by nucleases and proteases (Demidov et al., 1994) 
R. Kurg et al. / Virus Research 000 (1999) 000-000 11 
and can act at the specific sequence on the DNA. 
Under our assay conditions sequence-specific 
PNA was capable of specifically inhibiting E2 
binding to its target site and also inhibit the 
replication of the papillomavirus origin in the 
cells when PNA was pre-bound to the origin 
plasmid, but it was not able to inhibit replication 
without pre-forming PNA-plasmid complex. In 
conclusion, our data suggest that PNA-s can be 
used as tools in research applications, however 
they have to be modified so that the kinetics of 
complex-formation with the recognition sequence 
under physiological salt conditions could be in­
creased considerably in order to be used as a 
antiviral drug. 
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